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Abstract
Neurofascin (NF) is a cell-adhesion molecule that is found at the nodes of Ranvier. The 186
kDa isoform of neurofascin (NF186) is expressed on the axon in the exposed node, and the
155 kDa isoform (NF155) is expressed on myelinating glia at the paranode. NF186 is essential
for clustering of sodium channels to the nodes while NF155 is needed for close paranodal inter-
actions between myelinating glia and axons. The neurofascins are found in both the peripheral
and central nervous system (PNS and CNS).
NF-specific autoantibodies were identified in serum of multiple sclerosis (MS) patients using
a proteomics approach with two-dimensional Western blotting of human myelin glycoproteins.
A monoclonal antibody (mAb) specific for NF was shown to induce axonal injury in an animal
model of MS, experimental autoimmune encephalomyelitis. This indicated that NF is a relevant
autoantibody target in patients with inflammatory diseases of the nervous system (central and
peripheral), but actual abundance of anti-NF autoantibodies is unknown.
The objectives of the thesis were the following: 1) Develop assays to detect autoantibodies
against human NF. 2) Determine the prevalence in patients with MS and with inflammatory
diseases of the PNS. 3) Characterize the reactivity by immunoglobulin isotyping, serial dilution,
epitope mapping, and staining of nodal structures in tissue sections. 4) Affinity purify anti-NF
antibodies from plasma exchange material. 5) Determine possible in vivo effects of anti-NF
antibodies in the PNS using a neuritis animal model.
First, we expressed the complete human NF155 and NF186 on the surface of stable human cell
lines, produced the complete extracellular portion of the NFs in HEK293 cells, and expressed
truncated variants of the NFs in E. coli. With these reagents, we set up three antibody detection
assays: cell-based assay by flow cytometry, ELISA, and Western blot. These assays were
validated using NF-specific monoclonal and polyclonal antibodies, and optimized with a test
cohort of serum samples.
We screened 687 serum and 48 plasma exchange samples from patients with MS (n = 233),
inflammatory diseases in the PNS (n = 294), and controls (n = 208). From serum analysis,
we observed low prevalence of anti-NF reactivity (3%) by flow cytometry and/or ELISA despite
broad reactivity in almost half of the serum samples analyzed by Western blot. Reactivity ob-
served by flow cytometry and by ELISA were congruent only in the patients with the highest
reactivities. The anti-NF antibodies were NF-isoform specific, mainly IgG subclasses, and at
high titres in some cases. Using truncated variants of NF fused to super green fluorescence
protein (sGFP), we showed that reactivity of anti-NF Abs was largely directed towards the mem-
brane proximal extracellular domains that are unique to each isoform, while the membrane
distal immunoglobulin-like domains and fibronectin domains were not recognized.
A small proportion (3%; 8/254) of patients with GBS and CIDP showed reactivity to human NF
by ELISA. A few showed a particularly high reactivity (up to 1:10 000 dilution) to NF. Two CIDP
patients showed a particularly high (up to 1:10 000 dilution) anti-NF155 reactivity by FACS and
ELISA, recognized paranodes in tissue sections, and exhibited dominant IgG4 subclass us-
age. Another CIDP patient who benefited from plasma exchange had a persistent anti-NF155
reactivity by ELISA in serum, and after affinity purification, anti-NF186 and -NF155 reactivity by
FACS and ELISA were detected in addition. These antibodies were mainly IgG3, with minor
contribution of IgM and IgA. To investigate possible functions of anti-NF antibodies in inflamma-
tory PNS diseases, we injected two different monoclonal antibodies (mAbs) into a P2-peptide
induced experimental autoimmune neuritis (EAN) animal model at disease onset. We found
that while the anti-NF mAbs prolonged and exacerbated clinical disease in these animals, they
could not induce disease on their own.
We detected NF-reactivity in a small proportion of MS samples (3%; 7/225) by ELISA and flow
cytometry. We obtained follow-up material from two NF-reactive patients and saw a persistent
NF reactivity in one of them. To increase detection sensitivity, we affinity purified anti-NF an-
tibodies from plasma exchange material of patients with MS (n = 8). IgG, IgM, and IgA were
isolated from most of the samples; they were found to recognize NF155 and to a lower extent
NF186 by ELISA and in a few also by flow cytometry. This indicates that low levels of anti-NF
antibodies exist in a proportion of MS patients.
In conclusion, 3% of serum samples from patients with PNS inflammatory neuropathies (GBS
and CIDP) showed reactivity by ELISA and none of the controls. In an animal model of au-
toimmune peripheral nerve inflammation, we showed, using two anti-NF mAbs, that antibody
targeting of NF can enhance and prolong disease course. This suggests that antibodies to NF
may be relevant for a small group of patients with peripheral inflammatory neuropathies. In MS
patients, 3% showed anti-NF reactivity by flow cytometry and ELISA. Furthermore, low levels of
anti-NF antibodies that could be detected by ELISA and flow cytometry after affinity purification
were additionally found in some MS patient samples that were unreactive by serum screening.
This raises the possibility that low levels of antibodies to NF are present in some MS patients
and may contribute to the pathogenesis of this chronic disease.
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1.1 Neurons and glia
The nervous system contains neurons and glia. Neurons receive sensory input, transduce this
information via electrical impulses to communicate with other neurons, and finally evoke bodily
responses to the sensations. Glia are supporting cells that insulate and nourish neurons, and
they regulate the chemistry of the extracellular space.
A neuron consists of a soma, an axon, and a varying number of dendrites. The soma con-
tains the cytoplasm and nucleus of the neuron; in particular, it is where protein synthesis and
cellular respiration takes place. The axon extends from the soma; the initial segment is the
axon hillock where action potentials are initiated, and the terminal segment is the axon terminal
where the axon passes on information to other cells. Dendrites branch out of the soma and
receive synaptic inputs from axon terminals of other neurons.
Glia refer to astrocytes, myelinating cells, ependymal cells, and microglia. Astrocytes regulate
the chemical content of extracellular space and fill the spaces between neurons. Myelinating
glia, oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral
nervous system (PNS), produce large amounts of myelin as part of their cell membranes to en-
sheath neuronal axons and provide trophic support. Ependymal cells line fluid-filled ventricles
in the brain and are involved in cell migration during neural development. Microglia are CNS
resident phagocytes that scavenge for damaged cells, plaques and infectious agents.
1.2 Impulse conduction
For a neuron to respond to stimuli and conduct impulses, it requires a membrane potential: an
unequal distribution of charge across the cell membrane. The membrane potential, negative in
the intracellular side and positive in the extracellular side, is established actively by ion pumps
and passively by ion channels. At rest, the sodium (Na+) - potassium (K+) pump exchanges
internal Na+ for external K+, and Na+ channels are closed while some K+ channels are open.
Thus, K+ ions are more concentrated inside the cell, and Na+ ions are more concentrated
outside the cell.
Neurons convey information to other cells through action potentials. An action potential is
essentially a rapid change in the membrane potential that propagates down the axon when
the cell is stimulated. It is generated when a stimulus induces Na+ channels to briefly open,
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allowing Na+ ions to diffuse into the nerve cell, thereby rendering the inside of the membrane
positive relative to the outside. Then K+ channels open and K+ ions diffuse out of the cell; the
inside of the membrane becomes more negative again. After a refractory period and without
further stimulation, the membrane potential returns to the resting state.
For information to travel from one cell to another in the nervous system, the action potential,
localized in only a small area of nerve cell membrane, must travel down the axon. When
an action potential occurs on one patch of membrane, the adjacent membrane patch have
opposite charges across the membrane in relation. Essentially an electric circuit is created
between the two patches of membrane, and the Na+ influx stimulates the adjacent membrane
patch to generate its own action potential. The conduction velocity depends on how far ahead
the depolarization of adjacent membrane area spreads, which depends on the diameter of the
axon and extent of myelination.
1.3 Myelination and saltatory conduction
Some axons are coated with myelin sheath to increase conduction velocity. Myelin is plasma
membrane extensions of oligodendrocytes in the CNS and Schwann cells in the PNS that en-
sheath the axon in successive compact layers while excluding cytosol. The thickness of the
myelin sheath is proportional to the axon’s diameter. Neurons are typically associated with
many such glial cells down the length of their axons. One region of myelin formed from a glial
cell is separated from the next by an unmyelinated area known as the node of Ranvier. Electri-
cal activity on the axon is confined to these nodes: as the myelin sheath is insulating, it is only
at the nodes where the axonal membrane is in contact with extracellular fluid and ions can flow
across the axonal membrane.
Impulse conduction of a myelinated axon require the impulse to jump over myelinated segments
to generate action potentials only at the nodes. This process is known as saltatory conduction.
Since ions can move across the axonal membrane only at the unmyelinated nodes, the passive
spread of depolarization from the excess positive ions in the cytosol upon an action potential
can extend to the next node with little loss; thereby triggering an action potential at the next
node. Thus, myelination of an axon significantly increases conduction velocity compared to
unmyelinated axons and allows for rapid neuronal signalling.
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Figure 1.1: Impulse conduction in myelinated and unmyelinated axons (taken from 2002
Encyclopedia Britannica, Inc.)
1.4 Molecular view of the myelinated axon
The myelinated axon is organized into four distinct, repeating domains: the node of Ranvier,
paranode, juxtaparanode, and internode (Salzer et al., 2008). These domains are interdepen-
dent for domain assembly and maintenance.
The node of Ranvier is the part of the axon that is exposed to the extracellular environment.
In the CNS the node is covered by perinodal astrocyte processes (Black and Waxman, 1988)
while in the PNS it is encased by interdigitating microvilli of adjacent Schwann cells and the
basal lamina (Salzer et al., 2008). The node is enriched with voltage-gated ion channels (Na+
and K+ channels) necessary for impulse conduction, as well as adhesion molecules NrCAM
and the 186 kDa isoform of neurofascin (NF186) (Salzer et al., 2008).
Axo-glial junctions are found at the paranodal region, where the axon and myelin are brought
to their closest proximity. Under the electron microscope, these junctions are a series of loops
that invaginate the axolemma and on each loop are a series of transverse bands that are also
known as septate-like junctions (Peters et al., 1991). The bands were later identified to be the
complex of Caspr and contactin-1 on the axonal surface and 155 kDa isoform of neurofascin
(NF155) on the glial paranodal loops (Sherman et al., 2005). These junctions promote cellular
adhesion and also form a barrier against the diffusion of ions between the node and internodes
during action potential conduction (Rosenbluth, 1995). Furthermore, they also maintain the
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Figure 1.2: Domains of a myelinated
axon: The axon in both the PNS and
CNS is organized into four distinct do-
mains: the internode, juxtaparanode
(JXP), paranode, and node. The node
is covered by interdigitating Schwann cell
microvilli in the PNS and by perinodal
astrocyte processes in the CNS. Para-
nodal loops (PL) form septate-like junc-
tions (SpJ) with the axon for attachment.
Myelinated fibres are covered by a basal
lamina in the PNS. Adopted from Poliak
and Peles (2003).
density of ion channels in the nodal complex by limiting lateral diffusion from the node (Rios
et al., 2003), as well as avoiding the displacement of juxtaparanodal components.
The juxtaparanodal region is localized between the paranodal and internodal region just under
the compact myelin. It is enriched with K+ channels that are involved in repolarization during
impulse conduction (Salzer et al., 2008). There are also adhesion complexes composed axonal
and glial contactin-2/TAG-1 and axonal Caspr2 (Traka et al., 2003). The internodal region is
the portion that is ensheathed with compact myelin. The glial cell and the axon are separated
by a periaxonal space, and their interaction involves cellular surface proteins (Yu and Bunge,
1975).
1.5 Neurofascin
Neurofascin is a cell adhesion molecule that is important for the formation and maintanence of
nodes of Ranvier. It comprises two major isoforms upon alternative splicing: neuronal isoform
NF186 and glial isoform NF155. Axonal NF186 and NrCAM interact with glial gliomedin in the
PNS to cluster Na+ channels at the node of Ranvier (Feinberg et al., 2010). Glial NF155 is
found at the axo-glial junctions to interact with axonal Caspr and contactin-1, forming a barrier
excluding the nodal complex from the internodes (Feinberg et al., 2010). NF186 is present on
the axon exclusively at the node and axonal initial segments (Zonta et al., 2008); NF155 is
found at the paranodal regions, on oligodendrocytes in the CNS and Schwann cells in the PNS
(Davis et al., 1996; Tait et al., 2000).
Disruption of NF function can result in defective saltatory conduction, stemming from paranodal
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Figure 1.3: Localization of neurofascins (NF155, NF186) at the node of Ranvier: NF186
is localized on the axon in the nodal region anchored to ankyrin G while NF155 is found in the
paranodes on the myelinating glial cell interacting with the contactin-1/Caspr complex. Other
adhesion molecules (ex. Caspr-2 and contactin-2) are found in the juxtaparanode. Sodium
channels are anchored to ankyrin G at the node of Ranvier while potassium channels are lo-
calized on the juxtaparanodal region. Adopted from from Meinl et al. (2010).
axo-glial junction disruption and redistribution of ion channels (Thaxton et al., 2010). Pan-NF
knockout mice show severe defects in node formation (Sherman et al., 2005) as well as loss
of the transverse bands (Sherman et al., 2005). Reconstitution of the paranodal adhesion
complex using NF155 knock-in cannot promote PNS nodal complex assembly without NF186
(Sherman et al., 2005), but in the CNS, either one of the neurofascin isoforms can rescue the
node of Ranvier (Zonta et al., 2008). While there are subtle differences between the nodes of
Ranvier in the CNS and PNS (Figure 1.2), NF155 and NF186 are found in both the CNS and
PNS at similar sites in the nodes (Poliak and Peles, 2003) (Figure 1.3).
1.6 Effects of myelin disruption
The function and integrity of a myelinated axon are dependent on the organization of the special-
ized domains induced by myelination, and disruption of this organization due to demyelination,
induced by inflammation for example, may lead to conduction block and axonal degeneration
(Nave, 2010).
Conduction block upon demyelination reflects the lack of insulating properties of myelin, the
localization of Na+ channels that remain at the sites of former nodes, and an inadequate pres-
ence of Na+ channels in the former internodal regions as well as the misexpression of other
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ion channels that impair impulse conduction (Salzer et al., 2008). Furthermore, any impulse
conduction along a demyelinated axon would require significantly more energy compared to
myelinated axons due to channel redistribution (Waxman, 2006). With remyelination, conduc-
tion is restored since once more the axon is insulated in some segments and the distance
between successive channel clusters is shortened (Honmou et al., 1996).
Distal axonal degeneration may also be induced by myelin disruption since myelinating glial
cells modify axonal properties during myelination. Although the exact cause is unknown, some
observations provide insight to possible contributing factors. Normal axonal transport in myeli-
nated axons is impaired when axo-glial junctions in the paranodal region are defective (Martini,
2001). Impulse conduction along demyelinated axons require more energy due to channel
redistribution and higher Na+ channel density, perturbing the energy balance as a result. Con-
sequently, the Na+ - calcium (Ca+) exchanger function fails, leading to high Ca+ levels inside
the neuron thereby trigger axonal degeneration (Nave, 2010). Loss of trophic and metabolic
support from glial cells (Nave and Trapp, 2008) as well as alterations of the axonal cytoskeleton
and chemistry (Salzer et al., 2008) may also contribute to the pathology.
1.7 Inflammatory diseases in the nervous system
The CNS and PNS are immune privileged sites: they are separated from the systemic immune
compartment by the blood-brain barrier (BBB) in the CNS and the blood-nerve barrier (BNB)
in the PNS. These barriers must be breached for immune factors to contribute to the myelin
disruption and damage in inflammatory nerve diseases. The BBB regulate transport of solutes
from blood to the CNS parenchyma (Owens et al., 2008). This barrier may be altered in an
inflammatory setting; supporting evidence comes from observations of delocalized proteins
at the tight junctions (Kirk et al., 2003) and metalloprotease alteration of the basal lamina (Liu
et al., 2008). The BNB restricts access of soluble mediators to the peripheral nerve, though less
restrictive than the BBB. The BNB is absent at the most proximal and distal parts of peripheral
nerve (ex. nerve roots and terminals, dorsal root ganglia) (Kieseier et al., 2012).
Demyelination can occur in the context of inflammation; it is a feature of some autoimmune
inflammatory diseases of the nervous system, such as Guillain-Barré syndrome (GBS) and
chronic inflammatory demyelinating polyneuropathy (CIDP) in the PNS, and multiple sclerosis
(MS) in the CNS. In these diseases, antibody and complement deposition, cellular infiltration,
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and varying degrees of axonal loss have also been shown (Lassmann et al., 2007; Kieseier
et al., 2012). Antibodies to myelin components may direct complement deposition and activate
immune cell activity resulting in myelin destruction (Wootla et al., 2011). As the myelin mem-
brane may protect axons from auto-reactive cytotoxic T cells, the loss of myelin may result in
secondary axonal degeneration (Lassmann et al., 2007). Furthermore, reactive radicals gen-
erated by activated microglia and macrophages may diffuse into the exposed axon to disrupt
mitochondria ATP generation (Nave, 2010; Smith et al., 1999), resulting in an energy imbalance
in the neuron.
1.7.1 Inflammatory demyelinating diseases in the PNS
Guillain-Barré syndrome is an acute inflammatory polyneuropathy of several subtypes that are
differentiated based on clinical presentation and underlying pathology. There is evidence that,
in some cases, infection and vaccination may trigger an aberrant immune response that sub-
sequently lead to a breakdown of the blood nerve barrier to trigger GBS manifestation (Hughes
and Cornblath, 2005). The GBS variant acute inflammatory demyelinating neuropathy (AIDP)
is characterized by multifocal segmental demyelination and inflammatory infiltrates (Yuki and
Hartung, 2012). Demyelinated axons are found at the spinal roots and peripheral nerves, of-
ten accompanied by axonal degeneration (Lehmann et al., 2009; Yuki and Hartung, 2012).
Demyelination was shown to be induced by serum taken from a proportion of GBS patients
(Harrison et al., 1984). Histological studies using patient tissue samples revealed deposition
of antibodies and activated complement on Schwann cells (Hafer-Macko et al., 1996) as well
as nerve infiltration of T cells and macrophages (Prineas, 1981). Furthermore, in an animal
model that resembles AIDP, myelin antigen-induced experimental autoimmune neuritis (EAN),
myelin protein specific T cells were found to be neuritogenic and Schwann cells were assaulted
by antibody mediated cytotoxicity as well as complement dependent cytotoxicity (Spies et al.,
1995; Lonigro and Devaux, 2009). Although the involvement of antibodies in the pathogen-
esis of AIDP is evident, the target of pathogenic autoantibodies in many patients is currently
unclear.
For the axonal GBS variant acute motor axonal neuropathy (AMAN), antigenic targets are bet-
ter defined. Antibodies to several gangliosides (ex. GM1, GD1a, GM1b, GalNAc-GD1a) and
complexes of these gangliosides were detected in patient serum (Kaida and Kusunoki, 2010).
These antibodies preferentially target the nodes of Ranvier and the motor nerve terminal. Fur-
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thermore, anti-ganglioside antibodies were found to exert pathogenic effects by complement
fixation and macrophage activation (Hughes and Cornblath, 2005) that could lead to conduc-
tion block and injury to Schwann cells though the myelin is mostly still intact (Lehmann et al.,
2009).
Chronic inflammatory demyelinating polyneuropathy (CIDP) involves proximal and distal func-
tional deficits (Koeller et al., 2005). It is characterized by nerve infiltration of T cells and
macrophages, and deposition of antibody and complement on myelinated nerve fibres (Koeller
et al., 2005). Increased levels of pro-inflammatory cytokines are found in the CSF and also in
serum, and more activated macrophages and T cells are found in circulation (Lehmann and
Hartung, 2011). It was suggested that some T cells activate residing macrophages, which then
enhanced phagocytosis and increased production of pro-inflammatory cytokines, proteases,
and reactive oxygen and nitrogen species (Lehmann and Hartung, 2011). In addition, anti-
body and complement deposits were found on Schwann cells and also in intraneural blood
vessels (Dalakas and Engel, 1980). The involvement of antibodies in CIDP is further sup-
ported by passive transfer experiments into an animal model of peripheral neuropathy (EAN) in
which antibodies from CIDP patients were shown to induce conduction block and demyelination
pathology (Yan et al., 2000). However, the antigenic targets of the pathogenic antibodies are
currently unknown.
1.7.2 Inflammatory demyelinating disease in the CNS
Multiple sclerosis (MS) is an inflammatory demyelinating disease that is heterogeneous in
pathogenesis (Lassmann et al., 2007). It is also variable in onset and progression: the ma-
jority of patients develop MS with a relapsing course that is followed by a progressive phase,
while some patients enter the progressive phase from the onset (Lassmann et al., 2007). MS
is characterized by demyelination with partial axonal preservation in lesions found in the CNS.
These lesions occur in the context of inflammation, though active demyelination may be in-
duced by different immune mechanisms: (1) T cell and macrophage mediated, (2) antibody
and complement mediated, (3) production of reactive radicals disturbing mitochondrial function
resulting in hypoxia, and (4) mild inflammation associated with oligodendrocyte degeneration
(Lassmann et al., 2001). In slowly expanding lesions in progressive MS, activated microglia
and rarely immune cell infiltration are present; it was hypothesized that demyelination in the
progressive phase is driven by soluble factors from immune cells that became compartmen-
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talized in the CNS (Lassmann et al., 2007). Besides demyelinating plaques, another hallmark
of MS is the presence of oligoclonal bands in cerebrospinal fluid (Disanto et al., 2012). The
involvement of autoantibodies in MS pathogenesis is further evident in patients who were un-
responsive to steroids but had greatly benefited from plasma exchange (Keegan et al., 2005),
where blood is separated from plasma and the plasma is exchanged with albumin prior to re-
turning the cellular components back into the patient. (Wootla et al., 2011). Autoantibodies to
myelin components (protein, lipid, carbohydrate) were found in some MS patients and some tar-
gets (ex. myelin oligodendrocyte glycoprotein, myelin basic protein, glycosphingolipids) were
identified (Wootla et al., 2011). However, confirmation of the antigen specificity of pathogenic
autoreactive antibodies is still lacking (Wootla et al., 2011).
1.8 Autoantibodies against neurofascin in inflammatory diseases
in the PNS and CNS
Neurofascin-specific autoantibodies were first detected in MS patients by Mathey et al. (2007)
using a proteomic approach. They found that some MS patients show such antibodies by two-
dimensional Western blot with human myelin glycoprotein. Functional studies revealed that
antibody targeting of neurofascin using a pan-NF monoclonal antibody (mAb) disrupted nerve
conduction in rat hippocampal slices in the presence of complement. Furthermore, in a T cell
transfer experimental autoimmune encephalomyelitis (EAE) model, the pan-NF mAb exacer-
bated clinical disease presumably by mediating axonal injury when the blood-brain barrier of the
CNS was breached (Mathey et al., 2007). Although the potential pathogenicity of anti-NF anti-
bodies was demonstrated, the frequency of these antibodies in MS patients is unclear.
Neurofascin-specific autoantibodies were also reported in patients with GBS and CIDP by De-
vaux et al. (2012) and Pruess et al. (2011). Devaux et al. had found that 43% of GBS patients
and 30% of CIDP patients showed IgG fixation at nodes or paranodes on teased nerve fibres
from rodents. They had further investigated the specificity of these antibodies and found that a
small subset (5%) of GBS/CIDP patients harbour antibodies to the extracellular domain of the
rat isoforms of NF186, gliomedin, or contactin. Pruess et al. had performed ELISA using rat
NF155 that is commercially produced in NS0 murine myeloma cells. They found a higher level
of NF reactivity in GBS patient group compared to healthy controls. Furthermore, in an animal
model of GBS, namely EAN, pathogenic antibodies against both isoforms of NF were found
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upon inducing disease by myelin homogenate injection (Lonigro and Devaux, 2009).
Previous studies to detect neurofascin-specific antibodies in human serum utilized Western
blotting with glycoprotein preparations from human myelin or recombinant rat NF155 from NS0
murine cells, ELISA using also the rat NF155, indirect immunofluorescence using rodent nerve
fibres, and HEK293-cell-based assay using the rat isoforms of NF. There are two obvious limi-
tations to these detection methods for potentially physiologically relevant antibodies to neuro-
fascin. First, with Western blot the protein antigen is denatured and antibodies detected may be
directed to hidden epitopes that are irrelevant for disease. Second, antibody detection assays
using rodent isoforms of the antigens may not detect antibodies specific to the human iso-
form of the protein antigen; the species-specific sequences of the protein antigens in addition
to species-specific post-translational modifications may elicit false positives against immuno-
genic rodent-specific differences and false negatives when a pathogenic epitope is absent or
hidden by modifications. These limitations confound the significance of the results obtained,
making it difficult to appreciate the disease relevance of anti-NF autoantibodies.

Chapter 2
Objectives and Strategy
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2.1 Objectives
Neurofascin isoforms 155 and 186 (NF155, NF186) are implicated as autoantibody targets in
demyelinating diseases in the peripheral and central nervous system, namely GBS, CIDP, and
MS. However, the methods used in previous studies have inherent limitations that hinder a
clear evaluation of the presence of such antibodies in these patient groups. These limitations
include the display of denatured protein which may present hidden epitopes that are irrelevant
for disease while masking conformationally intact relevant epitopes, and the use of rodent NF
rather than human NF which introduces a cross-species difference to confound the results. The
pathogenicity of antibody targeting of neurofascin in the central nervous system was shown
using an experimental autoimmune encephalomyelitis model in which a monoclonal pan-NF
antibody exacerbated clinical disease. However, such pathogenicity has not been shown in
any peripheral nerve disease model.
Here we want to clearly determine the frequency of anti-human-neurofascin autoantibodies
among patients with GBS, CIDP, and MS and characterize the reactive antibodies for functional
significance. Furthermore, we evaluate the pathogenic potential of anti-NF antibodies in the
context of peripheral demyelinating conditions.
2.2 Strategy
We developed assays to detect serum antibodies specific for human NF155 and NF186. We
started by cloning human NF155 and human NF186 from human brain RNA, and recombinantly
expressing the proteins in human cell lines as a cell-bound form and a soluble form. Then we
established three antibody detection assays: cell-based assay by flow cytometry, ELISA, and
Western blot; they were validated using two anti-NF mAbs and NF155-specific rabbit serum.
The NF155 and NF186 were displayed in their native conformation on the transfectants for flow
cytometry, in a denatured state on a Western blot, and in a conformation that was neither native
or completely denatured when they were adsorbed onto the solid support for ELISA. We used
a test cohort of patient samples to optimize the assays to maximize sensitivity and clarity of
results.
We investigated the frequency of anti-human NF155 and NF186 antibodies in the serum of pa-
tients with demyelinating disease of the PNS and CNS (GBS: AIDP and AMAN, CIDP, MS) with
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our optimized assays. For comparison, we included serum samples from healthy donors and
from patients with other neuropathies, non-demyelinating nervous system disease amyotrophic
lateral sclerosis (ALS), and other non-inflammatory neurological diseases. The positive sam-
ples that we identified were further tested for nodal or paranodal recognition on tissue sections.
Since we suspected low levels of NF reactivity in relapsing-remitting MS (RRMS) patients, we
purified NF-specific antibodies by affinity chromatography from plasma exchange material of
these patients and tested them for reactivity in our assays.
To probe for disease relevance, we characterized the reactive antibodies of positive samples
by performing serial dilution and isotyping, and by determining specific domain recognition on
the NFs. Furthermore, we investigated potential pathogenicity of NF-targeting in peripheral
neuropathies by inducing experimental autoimmune neuritis (EAN) in rats with P2-peptide im-
munization and injecting monoclonal anti-pan-NF antibodies at disease onset. To provide a
coherent picture, I included experiments performed by colleagues or collaboration partners.
People involved in the analyses are mentioned in the relevant sections.

Chapter 3
Material and Methods
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3.1 Molecular cloning
3.1.1 Molecular biological methods
3.1.1.1 Reverse-transcriptase polymerase chain reaction (RT-PCR)
Superscript III reverse transcriptase (Invitrogen, Darmstadt, Germany) was used to synthesize
cDNA (700-900 bp) from human brain RNA (prepared by Dr. Tobias Derfuss). The reaction
was performed according to the protocol provided by the manufacturer using buffers provided
in the kit and self-designed NF sequence specific primers directed to the cytoplasmic region
and to the region between immunoglobulin-like domain-2 and -3 (Ig-2, Ig-3; primers listed in
Table 3.1). For each RT-PCR reaction, 1 µg of human brain RNA was used as template, and
the resulting cDNA product was used for amplification by polymerase chain reaction.
3.1.1.2 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) was performed using a thermocycler (Biometra, Goettingen,
Germany) for two main purposes: (1) amplication of DNA fragment for molecular cloning, and
(2) screening of bacterial colonies for plasmid of interest. All primers were designed to have
an annealing temperature between 58-64 ◦C and were synthesized by Metabion (Martinsried,
Germany). A typical amplication reaction involved a sample of template DNA (ex. cDNA, PCR
product, plasmid, bacteria cells), two oligonucleotide primers, deoxynucleotide triphosphates
(dNTPs), reaction buffer, magnesium, and a thermostable DNA polymerase. Taq DNA poly-
merase (Roche, Penzberg, Germany) was used unless otherwise specified. The reaction in-
volved an initial denaturing step at 95 ◦C for 2 min. This was followed by typically 25-40 cycles
consisting of: (1) Denaturation step at 95 ◦C for 2 min, (2) Annealing step at between 53-62 ◦C
for 1 min, and (3) Elongation step at 72 ◦C for 1-2 min. The duration of the elongation step
depended on the length of the expected PCR product (1 min for 1 kbp). The elongation time of
the final cycle was set to 10 min to ensure that all products were fully extended. Afterwards, it
is stored at 4 ◦C.
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Typical PCR mixture:
Molecular cloning Colony screening
5 µL 2 µL 10x Buffer with MgCl2
1 µL 0.4 µL 10 mM dNTP
0.25 µL 0.1 µL Forward primer
0.25 µL 0.1 µL Reverse primer
0.5 µL 0.2 µL Taq DNA polymerase
2 µL DNA Bacterial cells Template
41 µL 17.2 µL Water
50 µL 20 µL TOTAL
3.1.1.3 Overlap-extension PCR
Overlap-extension PCR is an efficient method to generate truncation mutants when restriction
endonuclease recognition sites are not available for precise cleavage and ligation. It is a simple
method where initial PCR products are generated with overlapping gene segments that can
then be used as templates for a subsequent PCR to create the full length construct.
Figure 3.1: OE-PCR
schematic from Heckman
and Pease (2007)
Referring to Figure 3.1, AB and CD are two separate DNA frag-
ments to be joined to form AD by overlap-extension PCR. The
internal primers (B and C) contain the overlapping sequence to
join AB and CD, while the outer primers (A and D) can only work
together to amplify the joined DNA template. The first step is to
separately generate AB and CD by PCR, and the second reac-
tion combines the first two PCR products using outer primers A
and D to amplify the hybrid product AD. KOD DNA polymerase
(Novagen, Darmstadt, Germany) was used because it is a high
fidelity thermostable polymerase that is superior in accuracy,
yield and processivity compared to other DNA polymerases cur-
rently available. The following details the reaction conditions
used:
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Fragment AB   Fragment CD
 2.0 µL     2.0 µL  KOD buffer 2
 1.2 µL     1.2 µL 25mM MgCl2
 1.6 µL     1.6 µL  2 mM dNTP
 0.1 µL     0.1 µL  Forward primer A or C
 0.1 µL     0.1 µL  Reverse primer B or D
 0.5 µL     0.5 µL  Template plasmid (5ng)
         13.5 µL             13.5 µL   Water
 1.0 µL     1.0 µL  KOD DNA polymerase
 
 20 µL   20 µL   TOTAL
Subsequently,
Fragment AD
10 µL + 10 µL  PCR-AB + PCR-CD
 3.0 µL  KOD buffer 2
 1.8 µL  25mM MgCl2
 4.0 µL  2 mM dNTP
 0.3 µL  Forward primer A
 0.3 µL  Reverse primer D
         20.6 µL  Water
 50 µL   TOTAL
1    Denaturation  94 °C  1 min
2    Denaturation  94 °C  15 sec
3    Annealing  55 °C  30 sec
4    Elongation  72 °C  20 sec
5    Elongation  72 °C  10 min
6    Pause   4 °C  ∞
20 cycles
1    Denaturation  94 °C  1 min
2    Denaturation  94 °C  15 sec
3    Annealing  55 °C  30 sec
4    Elongation  72 °C  1 min
5    Elongation  72 °C  10 min
6    Pause     4 °C   ∞
30 cycles
3.1.1.4 Cloning primers for NF155, NF186, and truncated NF variants
Table 3.1: Cloning primers for NF155, NF186, and truncated NF variants
Description Name Sequence
1 RT-PCR NFASC-RT-inIg3 ATG TCT GGT GTT GGG AC
2 RT-PCR NFASC-RT1-Cyt CAG AGA TGT CTG ACT GC
3 NF cloning NFASC-SalI-for GTC GAC ATG GCC AGG CAG CCA CCG
4 NF cloning NFASC-IgG2/3-HindIII-rev ACA TGA AGC TTG GTG TTC TTT C
5 NF cloning NFASC-Fn2-Fn3-for GGT TAC TCC GGA GAA GAT TAT C
6 NF cloning NFASC-Fn2-Fn4-for GGT GAA TCC GGA GAA GAT TTA CCC
AG
7 NF cloning NFASC-Bgl2-TM-Cyt-rev AGT AGA TCT TCA GCC GCG ACT CCT
CTT GAT G
8 NF with HIS tag NFASC-soluble rev CAG TAG ATC TTA GTG ATG GTG ATG
GTG ATG GCC CTG GGT GGC GAT GTC
9 pET F1 primer NFSC-F1 for TAT AGT ACT ATG GGA GCC ATC GAA
ATT CCT ATG
10 pET F1 primer NFSC-F1 rev CAG TAG ATC TTA GTG GTG ATG GTG
ATG GTG ATC CAG CAC ACT GAC AAA
GG
11 pET F2 primer NFSC-F2 for TAT AGT ACT ATG GTC AGT GTG CTG
GAT GTG C
12 pET F2 primer NFSC-F2 rev CAG TAG ATC TTA GTG GTG ATG GTG
ATG ATC TTC TCC GGA GTA ACC GAT
13 pET F3-5 primer NFSC-155-F3 for TAT AGT ACT ATG TCC GGA GAA GAT
TAT CCC AGG
14 pET F3-8 primer NFSC-186-F3 for TAT AGT ACT ATG GGA GAA GAT TTA
CCC AGT GC
15 sGFP forward for RSV5neo SuperGFP-Xba1-Cla1-for GC TCT AGA GCC ATC GAT GGC GGA
GGT GGC AGC ATG GTG AGC AAG GGC
GAG
16 sGFP reverse for RSV5neo SuperGFP-Xba1-rev GC TCT AGA GC TTA GTG ATG GTG ATG
GTG ATG
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17 6Ig TM fragment for NF-6Ig-Sal1-Nhe1-for A CGC GTC GAC TCT CTA GCT AGC TGA
TCA GGC CAC TAA CAA CCA AGC GGA
CAT CG
18 6Ig TM fragment rev NF-Cyt-Cla1-rev GCC ATC GAT GGC GCC GCG ACT CCT
CTT GA
19 Fn1Fn2 fragment 1 Fn1Fn2-Sal1-Signal-for TAT GTC GAC ATG GCC AGG CA
20 signal seq reverse Fn1Fn2-signal-overlap-rev AAC GGT TAG TCG GCT GCG TCA GCT
CAT TC
21 Fn1Fn2 fragment 2 Fn1Fn2-overlap-gene-for GAC GCA GCC GAC TAA CCG TTT GGC
TGC CCT
22 Fn1Fn2 fragment 2 Fn1Fn2-gene-Mro1-rev TC TTC TCC GGA GTA ACC GAT G
23 Fn1Fn2 fragment 3 Fn1Fn2-Mro1-TM-for GTT ACT CCG GAG AAG ATT ACA CCA
ACA ACC AAG CGG
24 Fn3Fn4 fragment1 Fn3Fn4-sig-overlap-rev AAT CTT CTC CCG GCT GCG TCA GCT
CAT TC
25 Fn3Fn4 fragment2 Fn3Fn4-f3f4-overlap-for GAC GCA GCC GGG AGA AGA TTA TCC
CAG GG
26 Fn4Muc fragment1 Fn4Muc-sig-overlap-rev AAT CTT CTC CCG GCT GCG TCA GCT
CAT TC
27 Fn4Muc fragment2 Fn4muc-f4muc-overlap-for GAC GCA GCC GGG AGA AGA TTT ACC
CAG TGC
28 Fn3 fragment2 Fn3-f2-overlap-Bst-rev TGT TGG TGT ATA CTC CTT CCG GGG
TGG TG
29 Fn3 fragment2 Fn3-f3-overlap-Bst-for GGA AGG AGT ATA CAC CAA CAA CCA
AGC GGA
30 Muc fragment1 Muc-sig-overlap-rev CTT CAT TCG GGG GCT GCG TCA GCT
CAT TC
31 Muc fragment2 Muc-muc-overlap-for GAC GCA GCC CCC GAA TGA AGC TAC
TCC AAC
3.1.1.5 Agarose gel electrophoresis
Agarose gel electrophoresis enables visualization of the purity, yield and size of DNA molecules
in a preparation. In addition, DNA molecules of different sizes are separated and can be se-
lectively eluted from the gel. To cast an agarose gel, agarose powder (Biozyme, Hessisch
Oldendorf, Germany) was dissolved in TBE buffer by heating and poured into a self assembled
mold with an appropriate comb. TBE buffer (10x) consisted of 108 g of Trizma base (Sigma-
Alrich, Munich, Germany), 55 g of Boric acid (Merck, Darmstadt, Germany) and 40 mL of 0.5
M EDTA (pH 8.0) in 1 L of water. The percentage of agarose in a gel varied depending on
the size of the DNA molecule of interest. In this work 0.8% to 1.5% agarose gels were used.
Ethidium bromide was added into the gel mixture at 1 µg/mL to visualize DNA under UV light
(λ = 254-366 nm). The gel was placed in TBE buffer in a horizontal electrophoresis chamber
and samples that were mixed with gel loading dye were loaded into the wells. Gel loading
dye (6x) consisted of 50% glycerin, 0.02% bromophenol blue (Serva, Heidelberg, Germany),
0.02% xylencyanol (BioRad, Munich, Germany), and 10 mM Trizma base (Sigma-Aldrich), and
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was adjusted to pH 7.5. DNA ladders (100 bp or 1 kb; New England Biolabs (NEB), Frankfurt,
Germany) were included for size recognition. The electrophoresis conditions were 100 mV for
30 min to 1 h at room temperature. Afterwards, the gel were visualized in a UV light box.
3.1.1.6 DNA extraction from agarose gel
DNA molecules were eluted from agarose gel pieces cut from the whole gel with a scalpel in
the UV light box. The elution was done using EasyPure kit (Biozyme) according to the protocol
provided by the manufacturer for a final elution volume of 12 µL.
3.1.1.7 DNA quantification
The amount of DNA in a solution was measured on a Nanodrop spectrophotometer (Peqlab,
Erlangen, Germany). First a blank measurement was done with the DNA buffer, then 2 µL
of DNA sample was loaded onto the stage for photometric measurement at 260 nm, and the
concentration and purity (from RNA and protein) of the DNA sample were measured.
3.1.1.8 DNA digestion with restriction endonuclease
Restriction digestion using endonucleases was performed on PCR products and plasmids.
Both conventional (New England Biolabs and Fermentas, St. Leon-Rot, Germany) and FastDi-
gest (Fermentas) formats were used. For a conventional restriction enzyme, 1 U is described to
be the amount of enzyme required to cleave 1 µg of substrate DNA in 60 min. For a FastDigest
enzyme, 1µL is made to cleave 1 µg of substrate DNA in 5-15 min. For each enzyme, the di-
gest reaction was carried out according to the manufacturer’s recommendation of buffer usage
and temperature for incubation. A consideration common to all digest reactions was that the
volume of enzyme used should not exceed 10% of total volume of the reaction, ensuring that
the glycerol concentration of the reaction remains less than 5%. In suboptimal conditions or
with prolonged incubation times, restriction enzymes are capable of star activity, which means
they can cleave sequences other than their defined recognition sequence. Double digest reac-
tions were carried out if there exists a compatible buffer and if the two recognition sequences
were sufficiently far apart from each other to avoid steric hindrance. Otherwise the cleavage
reactions were done sequentially, using alcohol precipitation (3.1.1.12) in between reactions to
precipitate the DNA and exchange the buffer.
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Table 3.2: Restriction enzymes used in this project
Enzyme Restriction site Manufacturer
Avr II C’CTAGG New England Biolabs
BamHI G’GATCC Fermentas
BglII FastDigest A’GATCT Fermentas
BsimI T’CCGGA -
BstZ17I GTA’TAC New England Biolabs
ClaI FastDigest AT’CGAT Fermentas
EcoRI G’AATTC New England Biolabs
HindIII A’AGCTT New England Biolabs
MroI T’CCGGA Roche
NheI G’CTAGC New England Biolabs
PmeI GTTT’AAAC New England Biolabs
SalI FastDigest G’TCGAC Fermentas
ScaI AGT’ACT New England Biolabs
SmaI CCC’GGG New England Biolabs
XbaI T’CTAGA New England Biolabs
3.1.1.9 DNA blunt end synthesis
DNA polymerase I large fragment (Klenow) from E. coli has 5’ to 3’ DNA polymerase and 3’
to 5’ exonuclease activities. It was used here to fill in the single-strand restriction endonucle-
ase termini to produce a double-strand blunt end. The large fragment of DNA polymerase I
kit (Invitrogen) was used and reaction conditions were according to the instructions from the
manufacturer.
3.1.1.10 DNA ligation
Fragments of DNA generated by PCR or by restriction digest were ligated to each other and
to the vector to produce a plasmid. After determining the DNA concentration of each fragment
or the linearized vector, a ratio of 1 (fragment) to 1 (fragment) was used to join fragments for
the insert and a ratio of 1 (vector) to 4 (insert) was used to form a complete plasmid. Ligation
reactions were set up as double ligation (1 insert, 1 vector) or triple ligation (2 fragments of the
insert, 1 vector). T4 DNA ligase (Invitrogen) was used here and reactions were set up according
to the protocol provided by the manufacturer, and incubated at room temperature for 30 min or
at 16 ◦C overnight. After the ligation reaction, 1-2 µL of the reaction was used to transform E.
coli cells (Section 3.1.2.1), typically DH5α or TOP10 (Invitrogen).
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3.1.1.11 TOPO TA cloning
TOPO TA cloning was used to amplify single DNA fragment molecules. It is an alternate method
to PCR for amplifying DNA fragments of interest. TOPO TA cloning kit (Invitrogen) was used
and the protocol from the manufacturer was followed. The technique involved a linear vector
with DNA topoisomerase I covalently attached to both free 3’ ends and PCR products with
adensine overhangs at the 3’ end. The free 5’ end of the PCR product attacks the 3’ end of
the vector, and the topoisomerase facilitates its ligation to the vector. This product was then
amplified by transformation into E. coli cells, typically TOP10 (Invitrogen).
3.1.1.12 Alcohol precipitation of DNA
Alcohol precipitation of DNA was carried out by adding 0.1 volume of 3 M sodium acetate and
2.5 volume of 100% ethanol to the mixture containing the DNA. The mixture was placed in
-80 ◦C for at least 30 minutes. After centrifugation at 14 000 rpm for 30 min at 4 ◦C, the DNA
was pelleted and the supernatant was discarded.
An alternative technique for small scale DNA precipitation is by using the Pellet Paint Co-
precipitant kit (Novagen). Pellet Paint is a non-fluorescent-dye-labelled carrier molecule that
enables visualization of the DNA pellet during alcohol precipitation which does not interfere with
downstream applications of the DNA. And the kit utilized the same mixture of sodium acetate
and ethanol as described above, with the addition of 2 µL of the labeling dye to each reaction.
After successive wash steps with 80-100% ethanol at room temperature, the DNA was pelleted
and could be used for downstream applications.
3.1.1.13 DNA sequencing
Sequencing of plasmids and PCR products was performed at the sequencing facilities provided
by the MPI of Biochemistry and the LMU Biocenter (both in Martinsried, Germany).
CHAPTER 3. MATERIAL AND METHODS 25
3.1.2 Microbiological methods
3.1.2.1 Transformation of bacterial cells
Plasmids were transformed into Escherichia coli (E. coli) cells for amplification. Typically, 10 ng
of plasmid preparation or 1 µL of ligation reaction was added into 50 µL of electro-competent
DH5α cells or chemically competent TOP10 cells.
For electroporation, the bacteria/plasmid mixture was transferred into a 2 mm Gene Pulser
cuvette (BioRad) and placed in the Gene Pulser electroporator (BioRad). The machine settings
were 25 µF, 200 Ω, and 1.8 kV, and the time constant was 3 - 4 msec. After electroporation, the
cells were transferred into 500 µL of Luria-Bertani (LB) medium (defined below) and incubated
in a 37 ◦C shaker at 150 rpm for 1 h to recover. After incubation, typically 20 µL, 50 µL, 100
µL of the transformed bacteria cells were plated on LB-Amp agar plates (defined below). The
bacteria plates were incubated overnight at 37 ◦C and the rest of the unplated bacteria culture
was stored at 4 ◦C.
Chemically competent cells were transformed by heat shock. In detail, 10 ng of plasmid prepa-
ration or 1 µL of ligation reaction was added into 50 µL of cells. After incubation on ice for 10
min , the cells were heated-shocked at 42 ◦C for 30 sec in a water bath, and then returned to
ice for 2 min. For recovery, 250 µL of SOC media (provided by Invitrogen) was added and then
the cells were placed in a 37 ◦C shaker at 150 rpm for 30 min. Afterwards, the cells were plated
on LB-Amp agar plates as explained previously.
LB medium (for 1 L in water) consisted of: 10 g Bacto-tryptone (BD Biosciences, Heidelberg,
Germany), 5 g yeast extract (BD Biosciences), and 10 g NaCl (Merck); it was brought to pH 7.5
using NaOH (Merck) and sterilized by autoclaving. For LB-agar, 15 g of agar was dissolved in 1
L of LB, sterilized by autoclaving, and for LB-Amp agar, ampicillin (Sigma-Alrich) was added to
a final concentration of 100 µg/mL; 20 mL was poured onto each 10 cm culture plate (Greiner,
Frichenhausen, Germany) for casting and the plates were stored at 4 ◦C until use.
3.1.2.2 Bacterial colony screening for plasmid identification
Bacterial colonies grown on agar plates with antibiotic selection were screened for the plasmid
of interest. Colony screening was done by PCR (as described in section 3.1.1.2) with a primer
combination that would only produce a product if the correct construct is present, ideally one
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primer specific to the vector and the other to the insert.
3.1.2.3 Plasmid purification from bacterial cells
Plasmid DNA was purified from E. coli cells while contaminating chromosomal DNA of the
bacteria was removed. This was done using miniprep and maxiprep kits (Qiagen, Hilden, Ger-
many). Using the protocol from the manufacturer, 20 or 500 µg of plasmid DNA may be recov-
ered from 5 or 500 mL overnight bacterial culure in LB-Amp using the miniprep or maxiprep kits
respectively. The resulting plasmid DNA was used for sequence verification, further cloning
procedures, or cell transfection.
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3.2 Recombinant protein expression
3.2.1 Generation of NF-expressing stable cell lines
Immortalized human cell lines were transfected with the pRSV5neo vector containing NF155TM,
NF186TM, or NF-truncation mutants fused to sGFP (refer to Table 4.1). Adherent host cell lines
obtained from the ATCC (Wesel, Germany) that were used here include: TE671 (human rhab-
domyosarcoma cells), HEK293 (human embryonic kidney), and HeLa (human cervical adeno-
carcinoma).
3.2.1.1 Cell culture conditions
All three wildtype cell lines were grown in complete Roswell Park Memorial Institute medium
(RPMI; Gibco, Darmstadt, Germany) media, which consisted of RPMI supplemented with 10%
fetal calf serum (FCS; Gibco), 1% Penicillin/Streptomycin solution (Gibco), and 1% sodium
pyruvate (Gibco). They were incubated in 37 ◦C with 5% CO2. The cells were passaged
once they reached 80-90% confluency by detachment with Trypsin-EDTA (EDTA = Ethylenedi-
aminetetraacetic acid; PAA Laboratories, Coelbe, Germany), rescue from the protease trypsin
with 3 volumes of complete RPMI media, centrifugation at 1000 rpm for 5 min at 4 ◦C, and sus-
pension in complete media for plating. Cell viability was assessed by mixing the cell suspension
1 : 1 with trypan blue solution (0.4%, 1:4 in phosphate buffered saline (PBS), pH 7.4; Invitrogen)
and quantifying on a hemocytometer under the microscope. The cells were typically grown in
T25, T75, or T175 cell culture flasks (BD Biosciences). PBS consisted of 137 mM NaCl, 2.7
mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4, and was adjusted to pH 7.4.
3.2.1.2 DNA plasmid preparation
To generate stable cell lines, the plasmids were linearized using ScaI restriction digest enzyme
(NEB). The reaction was set up according to the instructions of the manufacturer and incubated
at 37 ◦C for 2 h. The DNA was then alcohol precipitated (Section 3.1.1.12) and stored in -80 ◦C.
For transfection, the precipitated plasmid sample was centrifuged at 14 000 rpm for 30 min at
4 ◦C to pellet the DNA. At this point the DNA preparation was sterile. Subsequent steps were
performed in a cell culture hood under sterile conditions. The supernatant was discarded and
the DNA pellet was left to air-dry at room temperature for 5 min.
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3.2.1.3 Transfection protocols
Transfection of human cell lines was done using two different techniques: electroporation and
by using FuGENE transfection reagent (Roche).
By electroporation
Transfection by electroporation typically required 5 million cells and 30 µg DNA in 1 mL of
RPMI. Both the cells and DNA were added into a cold 0.5 cm Gene-Pulser cuvette and kept
on ice. For electroporation, the Gene Pulser along with the Gene Pulser Capacitance extender
were set to 0.280 kV and 960 µF. The time constant was 17 - 22 msec. Afterwards, the cells
were transferred into 6 mL of prewarmed complete RPMI media, and divided into six 10 cm
cell culture dishes containing 9 mL of prewarmed media. Antibiotics were applied 48 h after
transfection (Section 3.2.1.4).
Using FuGENE transfection reagent
To transfect cells with FuGENE 6 Transfection reagent (Roche), 500 000 cells were plated into
each well of a 6-well cell culture dish. They were left in the incubator for at least 4 h to adhere.
A ratio of 6 µL Fugene to 2 µg plasmid DNA was used, and the volume was made up to 100 µL
of RPMI. The mixture was allowed to sit at room temperature for 15 min, and then it was added
dropwise into the culture. The cells were cultured in the transfection solution overnight, and
on the following day replated with fresh media. Antibiotics were applied 48 h after transfection
(Section 3.2.1.4).
3.2.1.4 Selection of transfected cells with antibiotics
Geneticin (Gibco) was used as a selection antibiotic with pRSV5neo plasmids. For TE671
and HEK293 cells, it was applied at three different concentrations: 1.5 mg/mL, 2.0 mg/mL, 2.5
mg/mL. For HeLa cells, the final concentrations used were: 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL.
Approximately 10-14 days later, colonies formed from single cells were visible and they were
individually picked to be expanded and screened for recombinant protein expression.
For cell lines expressing the complete NF155 and NF186 on the cell surface, the expression
level of the recombinant protein was determined by flow cytometry using a monoclonal anti-
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pan-NF antibody (A12/18.1, Table 3.5.1; section 3.5.2.1 for details on flow cytometry). For cell
lines expressing truncated versions of NF155 and NF186 fused to sGFP, the intensity of the
sGFP fluorescence was measured by flow cytometry as an indirect indication of the level of
truncated NF expression.
3.2.1.5 Maintanence of stable cell lines
Once a transfected cell line was established, it was maintained in complete RPMI supplemented
with 1 mg/mL geneticin. Each group of cell lines to be used for direct comparison were grown
in synchrony, meaning that the cell lines of a particular group were passaged together using
the same media and plated at the same density in a new bottle at each passage so that they
were kept as similar as possible.
3.2.1.6 Storage of stable cell lines
The cell lines were resuspended at 5 million cells per mL in freezing medium: FCS in 10%
dimethyl sulfoxide (DMSO; Merck). DMSO is a cyroprotectant used to protect cells from dam-
age during freezing. The suspension was transferred into a cryotube vial (NUNC) to be frozen.
The freezing medium was kept cold because DMSO is toxic to cells at high concentrations.
The cryotube was placed in an indirect alcohol bath (Nalgene) to be placed in -80 ◦C so that
the cells could be slowly brought to -80 ◦C as the alcohol cools down. The filled cyrotubes were
transferred into liquid nitrogen tanks for long-term storage 24 h afterwards.
3.2.2 Generation of soluble NF by transient protein expression
The extracellular domains of NF155 and NF186 were expressed in suspension HEK293-EBNA
cells in serum-free conditions. HEK293-EBNA cells are human embryonic kidney cells that are
stably transfected with a plasmid encoding Epstein-Barr virus nuclear antigen (EBNA) under
geneticin selection. The EBNA allows for episomal amplication of plasmids that contain the viral
EBV origin of replication (EBV-ori). Thus, by transfecting a plasmid containing EBV-ori into the
cells, more copies will be generated which enhances the level of protein production. We used
the pTT5-vector; it contains the EBV-ori as well as human cytomegalovirus (CMV) promoter,
which is a strong transcription promoter. An adenovirus E1a/E1b fragment that is integrated
in the genome of the HEK293 cells further enhances the CMV promoter. Thus, significant
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amounts of recombinant protein may be produced. The HEK293-EBNA/pTT5-vector protein
expression system was described Durocher et al. (2002) and was patented by Yves Durocher
at NRC Biotechnology Research Institute in Canada (Patent nr. 20110039339).
3.2.2.1 Cell culture conditions
HEK293-EBNA cells were grown in suspension in Freestyle293 Expression Medium (Gibco)
supplemented with 1% Pluronic F-68 (10%) (Gibco) and 25 mg/L geneticin (Gibco) in vented
flasks (Corning, Amsterdam, Netherlands) in a Multitron shaker (Infors, Einsbach, Germany) at
37 ◦C, 5% CO2, 70% humidity, and 90 rpm. They were passaged at 2 million cells per mL.
3.2.2.2 DNA plasmid preparation
Plasmids for transfection (pTT5-NF155sol and pTT5-NF186sol) were amplified in E. coli and
purified by maxiprep (Qiagen, refer to section 3.1.2.3). The resulting plasmid preparation was
dissolved in EB buffer (provided in maxiprep kit, Qiagen) and was directly used for transfec-
tion.
3.2.2.3 Transfection using Polyethylenimine (PEI)
For transfection, viable HEK293-EBNA cells were adjusted to 1 mil/mL. The transfection mixture
for 100 mL of cells was made by mixing (1) 1mL Optipro SFM (Gibco) containing 100 µg of
plasmid DNA with (2) another 1 mL Optipro SFM containing 200 µL of jetPEI DNA transfection
reagent (Polyplus Transfection). The mixture was left at room temperature for half an hour, and
then added dropwise into the cell suspension while the culture was swirled. After 24 h, a Bacto
TC Lactalbumin hydrolysate (BD Biosciences) solution was added to the culture to 0.5% final
concentration.
3.2.2.4 Harvesting of supernatant
After 96 h, the cell culture was harvested: the cells and cell debris were separated from the
supernatant that contained soluble neurofascin first by centrifugation at 1 500 rpm for 5 min
at 4 ◦C, and then by ultracentrifugation at 10 000 rpm for 15 min at 4 ◦C. The resulting super-
natant was filtered using a 0.22 µm pore-size ExpressPLUS Stericup (Millipore), and the pH
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was adjusted to pH 8.0.
3.2.2.5 Purification and preparation of soluble NF
The HEK293-EBNA cells secreted recombinant soluble NF with a C-terminal His-tag into the
supernatant. The His-tag exhibits binding affinity to several types of metal ions, such as nickel
and cobalt. For purification, our resin of choice was Ni-NTA agarose (Qiagen): a resin with
immobolized Ni2+ ions. Typically 1 L of supernatant was loaded onto the 20 mL column by
gravity flow at 4 ◦C overnight. The column was eluted using a fast protein liquid chromatogra-
phy (FPLC) setup (Pharmacia). The protein purification procedure using Ni-NTA matrix on the
FPLC is explained in detail in Section 3.3.1.1. The eluted protein was concentrated and buffer-
exchanged with PBS using Ultracel 10 k spin tubes (Millipore) according to the manufacturer’s
instructions. The resulting protein preparation was stored as 1 mL aliquots at -20 ◦C. The con-
centration of the protein preparation was measured photometrically at 280 nm by Nanodrop
(Peqlab) or by bicinchoninic acid (BCA) assay (details in Section 3.3.4).
3.2.3 Protein expression in bacterial cells
Fragments of the extracellular domains of NF155 and NF186 were produced in Rosetta E. coli
(Novagen). The Rosetta strain is a derivative of Bl21 that is modified for enhanced expression
of eukaryotic proteins that contain codons rarely used in E. coli. We used pET21c(+)-vector
so that the transgene is expressed under the control of strong bacteriophage T7 transcription
and translation signals. T7 RNA polymerase expression is induced in the host cell by isopropyl
β-D-1-thiogalactopyranoside (IPTG) addition, and only with IPTG induction is the transgene
expressed.
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Figure 3.2: Double induction by IPTG: The Rosetta cell λDE3 lysogen encodes the T7 RNA
polymerase. When IPTG is absent, the lac I gene is constitutively expressed and the lac re-
pressor inhibits transcription of both the T7 RNA polymerase and the transgene of the plasmid.
In the presence of IPTG, T7 RNA polymerase is expressed as the lac repressor is inhibited
and it can transcribe the transgene for recombinant protein production. Taken from Novagen,
Innovations, vol. 1, number 1, 1994.
3.2.3.1 Transformation of Rosetta cells
To transform the chemically competent Rosetta E. coli cells, 10 ng of plasmid was mixed with 50
µL of cells, and then the cells were heat shocked as described in Section 3.1.2.1. Afterwards,
they were grown in 20 mL LB-Amp overnight in a 37 ◦C shaker at 150 rpm.
3.2.3.2 Protein expression by IPTG induction
Rosetta cells transformed with a pET21c(+)-vector containing the transgene of interest were
induced to express the recombinant protein with IPTG addition. In detail, 1 mL of the overnight
culture was used to innoculate 250 mL of LB-Amp. The culture was grown in the 37 ◦C shaker
at 150 rpm. The rate of cell growth was monitored hourly by photometric measurement of
bacterial cell density at 600 nm. When OD600 reached 0.4, IPTG (Invitrogen) was added to
a final concentration of 1 mM. The culture was allowed to grow until the OD600 reaches 2.
Then the culture was harvested by centrifugation at 5 000 rpm to pellet the Rosetta cells. The
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supernatant was removed and the pellet was frozen at -20 ◦C until purification.
3.2.3.3 Protein purification
To recover the recombinant protein, the cell pellet was first resuspended in lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazol; Merck) supplemented with 100 mg/mL lysozyme
(Sigma-Alrich), 50 µg/mL deoxyribonuclease I (DNase I; Sigma-Alrich), 10 mM MgCl2 (Merck)
and 100 µM phenylmethylsulfonyl fluoride (PMSF; Sigma-Alrich). The cell pellets varied from 5
g to 8 g; 4 mL of lysis buffer was used per gram. The cell suspension was incubated on ice for
30 min, and sonicated on ice using the sonicator (Bransen Sonifier 450) set at 50% duty and
20% power for 10 bursts of 10 sec sonification followed by 10 sec rest. The sonicator produces
high frequency sounds waves to shear cells. Afterwards, the cell lysate was centrifuged at 10
000 rpm for 30 min at 4 ◦C to separate the cell debris from the soluble protein in the supernatant.
At this point, a proportion of the recombinant protein was found in the supernatant while the
rest remained in the pellet. The supernatant was kept at 4 ◦C and the pellet was resuspended
in 20 mL of solubilization buffer containing 8 M Urea (Merck) and 150 mM NaCl by vortexing
and incubated at room temperature for 1 h. Afterwards, the pellet suspension was centrifuged
for 30 min at 10 000 rpm at 4 ◦C to separate the solublized protein from cell debris.
The next step was to separate the target protein from other contaminating proteins present in
the supernatant. Since the target protein was designed with a His-tag in the C-terminus, it was
purified from the supernatant using Ni-NTA agarose (Qiagen). The supernatant was loaded
onto a 5 mL Ni-NTA agarose column by gravity flow, washed extensively with lysis buffer and
then with PBS, and the target protein was eluted with PBS containing 500 mM imidazol. The
amount and purity of the target protein eluate was visualized on an SDS-PAGE gel (Section
3.3.2.1).
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3.3 General protein analytics
3.3.1 Protein purification by fast protein liquid chromatography
To separate a target protein from a protein mixture, fast protein liquid chromatography (FPLC)
was used. It is a machine that uses medium pressure to separate proteins based specific prop-
erties of the target protein such as size (gel filtration), hydrophobic interactions, affinity to a lig-
and, and charge distribution (ion exchange). The present work utilized affinity chromatrography
based on the affinity of histidine to specific metal ions (section 3.3.1.1), antibody Fc fragment
to protein G (section 3.3.1.2), and antibody to its antigen (section 3.5.8). The columns were
eluted at the FPLC setup (Pharmacia) which consisted of two pumps connected to a central
controller, an absorbance monitor set to 280 nm, and a pen-recorder to record the absorbance
readings.
3.3.1.1 Immobilized metal affinity chromatography
The soluble recombinant proteins produced for this study were extended by a polyhistidine tag
(His-tag) at the C-terminus. The His-tag is an amino acid motif consisting of at least 5 histidine
residues; this motif is capable of binding to several types of immobilized metal ions, including
nickel, cobalt and copper. Beaded agarose supports are produced with chelating groups such
as nitrilotriacetic acid (NTA) that can immobilize metal ions; NTA-agarose may be charged with
Ni2+ to form Ni-NTA agarose (Qiagen).
Ni-NTA agarose was packed into a column bed, and the solution containing the target protein
was first adjusted to pH 8.0 before it was passed through. Unspecific protein binding was
washed off using PBS containing 20 mM imidazol (Merck). To recovery the target protein, the
column was eluted with PBS containing 250 mM imidazol. Both wash and elution steps were
monitored on the absorbance reader at 280 nm. Subsequently, the eluted protein was further
concentrated and dialyzed against PBS.
3.3.1.2 Affinity purification of antibodies using Protein G
To purify IgG antibodies from serum or cell culture supernatant, affinity chromatography on
columns of gels derivatized with bacterial protein G was used. Protein G is a protein from
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group G Streptococci that can bind antibody Fc region of mainly IgGs from various species (ex.
human, mouse, rat, rabbit, bovine). The naturally occurring form of protein G also bind albu-
min; however, it is commercially available as a recombinant protein with the albumin-binding
region deleted. This recombinant protein is covalently coupled to sepharose to form Protein G
sepharose (GE Healthcare).
Protein G sepharose was packed into a column bed, and the antibody solution at neutral pH
was passed through. Unspecific binding of protein onto the matrix was washed off with PBS
until the absorbance reading at 280 nm was back to baseline. The antibodies were eluted
with 100 mM glycine-HCl buffer with 150 mM NaCl, adjusted to pH 2.7. The acidic eluate was
immediately neutralized by 100 µL of 1 M Tris-HCl at pH 9.0 that was previously added to each
fraction tube. The eluted antibodies were dialyzed against PBS in 12-16 kDa cutoff dialysis
tubing cellulose membrane (Sigma-Alrich) and stored in PBS at -20 ◦C.
3.3.2 Protein separation and analysis
Proteins may be separated according to their electrophoretic mobility, which is a function of the
length of the polypeptide chain and its charge. In most cases, sodium dodecyl sulfate (SDS)
is applied to the polypeptide chain to render an even charge distribution so that proteins are
separated specifically by size. SDS polyacrylamide gel electrophoresis (SDS-PAGE) is a very
convenient way to visualize the purity of a protein preparation and to estimate the size of a
protein relative to the molecular size markerr on the gel. To visualize the separated proteins,
the gel may be stained by Coomassie blue or by silver. Coomassie blue staining is much less
sensitive than silver staining and its main purpose is only simple protein verification. By silver
staining, as little as 5 ng of protein may be detected and it was done to monitor the purity of a
protein preparation.
3.3.2.1 Gel electrophoresis
Precast 4-12% Bis-Tris gels (Invitrogen) were used in this study. As the protein sample travel
through the gel, the narrowing pores exert a sieving effect so that the smaller proteins can travel
faster through the matrix while the larger proteins slower. The gel was fitted into an XCell elec-
trophoresis chamber (Invitrogen) filled with NuPAGE MOPS SDS running buffer (Invitrogen).
NuPAGE LDS sample buffer (Invitrogen) was mixed with the protein sample and incubated at
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95 ◦C for 5 min prior to loading into the gel. For sample preparation in reducing conditions,
β-mercaptoethanol (Merck) was added to 5% final concentration before the heat incubation
step. A full-range rainbow molecular weight marker (GE Healthcare) was used as a reference
to estimate the size of proteins on the gel. Electrophoresis was performed typically for 1 h at
200 V.
3.3.2.2 Protein staining by Coomassie brilliant blue
The protein gel was incubated for 20 min in Coomassie blue solution (0.1% (w/v) Coomassie
brilliant-blue R-250, 40% methanol, 10% acetic acid) and then 1 h in destain solution (50%
methanol, 7% acetic acid) on a shaker at room temperature. The destain solution was changed
several times in that hour. To further remove background staining and enhance the contrast to
visualize the protein bands, the gel was then incubated in 10% acetic acid solution overnight
at 4 ◦C on a shaker.
3.3.2.3 Protein staining by silver
The protein gel was fixed in 50% methanol with 5% acetic acid for 20 min at room temperature
and then washed for 10 min with 50% methanol followed with another 10 min with water. Then
the gel was sensitized with 1 min incubation in 0.02% sodium thiosulfate. After rinsing with
water, the gel was submerged in a cold 0.1% silver nitrate solution for 20 min at 4 ◦C. After
washing with water, the gel was developed in a solution containing 0.04% formalin and 0.2%
sodium carbonate. The gel was gently shaken in the developing solution, which was discarded
when yellow to reduce background staining of the gel and was replaced by fresh solution. After
the desired intensity of protein staining was achieved, the reaction was terminated by addition of
5% acetic acid. For storage, the stained gels were kept in 1% acetic acid solution at 4 ◦C.
3.3.3 Mass spectrometry
Protein bands of interest may be identified by mass spectrometry. The protein band was cut
from the stained gel with a scalpel, chopped into smaller fragments and stored in 50 µL of
water. Afterwards, it was sent to the mass spectrometry service at the MPI of Biochemistry
(Martinsried, Germany).
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3.3.4 Measurement of protein concentration
3.3.4.1 Bicinchoninic acid assay
The bicinchoninic acid assay (BCA assay) was used to measure the total amount of protein in a
solution. The concentration of protein is estimated colourmetrically when the solution changes
from green to purple in proportion to protein concentration.
In detail, the assay is based on two chemical reactions. The first step is the biuret reaction:
the peptide bonds reduce Cu2+ ions from cupric sulfate to Cu+ ions in an alkaline medium
to produce a faint blue-violet colour. The amount of reduction is proportional to the amount
of protein present. The second step involves the chelation of two molecules of BCA with the
Cu+ ions to produce the intense purple colour that has a strong linear absorbance at 562
nm. This assay is compatible with the presence of detergents, but not reducing agents and
chelators.
For each sample, the concentration was measured in duplicates or triplicates using the BCA
protein assay reagent kit (Pierce, Rockford, USA) according to the instructions of the manu-
facturer. A standard curve of known concentrations of bovine serum albumin (BSA; Serva,
Heidelberg, Germany) was used to estimate the concentration of test samples. The reaction
mixture was incubated for 30 min at 37 ◦C and absorbance at 550 nm was measured.
3.3.4.2 UV spectrophotometry by Nanodrop
The concentration of a protein sample was also measured using Nanodrop 1000 (Peqlab). Be-
tween 0.5 µL to 2.0 µL of sample was used to make absorbance at 280 nm. It is a fast and
convenient method, requiring no additional reagents, incubation time, or standard curves. How-
ever, as amino acids with aromatic rings (phenylalanine, tryptophan, histidine and tyrosine) are
responsible for the absorbance peak at 280 nm, different proteins will exhibit different absorp-
tion characteristics. Furthermore, the absorption characteristics of each protein are dependent
on enviromental factors that can affect the structure, like pH and ionic strength.
3.3.5 Circular dichroism spectroscopy
The conformation of the soluble recombinant proteins generated from HEK293-EBNA cells was
analyzed by circular dichroism spectroscopy (CD spectroscopy). CD spectroscopy measures
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differences in absorption of left-handed polarized light versus right-handed polarized light that
arise from structural asymmetry. Thus, this method is based on the optical activity of protein
from the chiral α-carbon atom of all amino acids except glycine, and especially secondary struc-
tures such as alpha-helices and beta-sheets. A CD spectra between 250-195 nm was analyzed
for secondary structures like alpha-helix, beta-sheet, turn and unordered structures.
CD spectroscopy was performed in the Microchemistry Core Facility at the MPI of Biochemistry
using J-715 spectrometer (Jasco, Gross-Ulmstadt, Germany). The spectra was recorded at
25 ◦C at a speed of 50 nm/min. Duplicates were done for each protein sample.
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3.4 Patient material
Serum and plasma exchange material from patients and serum from healthy donors were used
in this project. In some rare cases, cerebrospinal fluid was also analyzed. Material from multiple
sclerosis patients came from the following donors: Prof. Dr. Frank Weber and Dr. Philipp Sae-
mann of the MPI of Psychiatry (Munich, Germany), Prof. Dr. Tomas Olsson and Dr. Mohsen
Khademi of the Karolinska Institute (Stockholm, Sweden), and the staff doctors at the Insti-
tute for Clinical Neuroimmunology at Klinikum Großhadern (Munich, Germany). Material from
patients with peripheral inflammatory neuropathies came from the following donors: Prof. Dr.
Nobuhiro Yuki and Dr. Masaaki Odaka of Dokkyo Medical University (Mibu, Japan), Dr. Bjoern
Tackenberg of Philipps University (Marburg, Germany), Dr. Harald Pruess, Dr. Jan Schwab,
and Prof. Dr. Lutz Harms of Charité (Berlin, Germany), Dr. Hendrik Harms of St. Josef-
Krankenhaus (Potsdam, Germany) and Dr. Sommer of the University Hospital of Wuerzburg
(Wuerzburg, Germany). Material from patients with amyotrophic lateral sclerosis came from
Dr. Johannes Brettschneider of University of Ulm (Ulm, Germany) and Prof. Dr. Harms. Con-
trol patients with other neurological diseases came from the Prof. Dr. Olsson and Dr. Pruess.
Serum from healthy donors were provided by Prof. Dr. Yuki, Dr. Pruess, Prof. Dr. Olsson, and
my colleagues at the MPI of Neurobiology. Details are listed in Table 3.3.
3.4.1 Ethical standard and patient consent
These studies were approved by the local ethical committee of each sample source and the
donors gave their informed consent.
3.4.2 Storage and handling of patient material
All patient material were stored at -20 ◦C, and were regarded as hazardous and treated as
potentially infectious specimens. Working aliquots of typically 50 µL were made with serum
samples for screening and characterization. Working volumes of between 200 mL and 1 L of
plasma exchange material was thawed for antibody purification, and the column flow through
was bottled, labelled and refrozen for future studies.
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3.4.3 Patient material list
Table 3.3: Patient material list
Source Disease Volume Number Age Male:Female
Multiple
Sclerosis
Serum MPI-Psychiatry RR-MS 500 µL 74 22-63 23:51
PP-MS 500 µL 6 38-72 4:2
SS-MS 500 µL 9 34-74 2:7
MS-unclassified 500 µL 2 58
CIS 500 µL 5 35-44 1:4
Karolinska Institute RR-MS 100 µL 124 17-69 46:88
PP-MS 100 µL 4 44-63 0:4
SP-MS 100 µL 2 57, 67 0:2
MS-unclassified 50 µL 4 - -
Plasma
exchange
Klinikum Großhadern RR-MS 1 mL 17 22-52 6:11
NMO 1 mL 3 31-51 1:2
RR-MS 200-1000 mL 8 22-52 5:3
Peripheral
Neuropathy
Serum Dokkyo University CIDP 100 µL 50 9-87 40:10
AIDP 100 µL 50 1-84 33:17
AMAN 100 µL 50 14-83 29:21
Philipps University CIDP 500 µL 30 20-90 23:7
Charité CIDP 100 µL 2 45, 61 2:0
AIDP 100 µL 4 23-53 1:3
St. Josef-Krankenhaus CIDP 500 µL 37 13-85 27:10
AIDP 500 µL 11 20-58 8:3
ALS 500 µL 16 35-80 7:9
ON 500 µL 20 20-78 19:1
University of Ulm ALS 500 µL 55 26-88 31:24
Plasma
exchange
University of Wuerzburg CIDP 1 mL 40 28-83 30:10
Control
donors
Serum Karolinska Institute OND 100 µL 57 21-80 13:44
Charité OND 100 µL 1 34 -
Karolinska Institute HC 100 µL 5 20-35 3:2
MPI Neurobiology HC 500 µL 21 21-55 9:12
Dokkyo University HC 100 µL 50 14-84 17:33
RR-MS = relapsing-remitting multiple sclerosis; PP-MS = primary progressive multiple sclerosis; SP-MS = sec-
ondary progressive multiple sclerosis; CIS = clinically isolated syndrome; NMO = neuromyelitis optica; CIDP =
chronic inflammatory demyelinating polyneuropathy; AIDP = acute inflammatory demyelinating polyneuropathy;
AMAN = acute motor axonal neuropathy; ALS = amyotrophic lateral sclerosis; ON = other neuropathies (including
diabetic polyneuropathy, monoclonal gammopathy, polyneuropathy from vitamin B12 deficiency, and polyneuropa-
thy with unclear origins); OND = other neurological (non-inflammatory) diseases (including sensory symptoms,
headache, migraine, vertigo, neurastenia, pain, cancer, and vascular problems); HC = healthy controls
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3.5 Antibody detection assays
3.5.1 List of primary and secondary antibodies used in this project
Table 3.4: List of primary and secondary antibodies used in this project
Specificity Conjugate Clone Species/Isotype Concentration Dilution Source
pan-NF - A12/18.1 mouse IgG2a 1-2 mg/mL 1:1000 in-house hybridoma
pan-NF - A4/3.4 mouse IgM 2 mg/mL 1:1000 Genovac
pan-NF - L11A/41 mouse IgG1 - 1:200 NeuroMab
NF155 - polyclonal rabbit IgG serum 1:100 in-house
Caspr - polyclonal rabbit IgG serum 1:1000 Peles et al. (1997)
Oligodendrocyte marker O4 - MAB345 mouse IgM 1.05 mg/mL 1:100 Chemicon
Galactocerebroside - MAB342 mouse IgG3 1 mg/mL 1:100 Chemicon
Olig-2 - polyclonal rabbit IgG - 1:200 Millipore
polyHistidine Peroxidase HIS-1 mouse IgG2a 5-11 mg/mL 1:2000 Sigma-Aldrich
mouse IgG HRP polyclonal goat F(ab’)2 0.8 mg/mL 1:7000 JacksonImmuno
R-PE polyclonal goat IgG - 1:200 Dako
Alexa488 polyclonal donkey IgG 2 mg/mL 1:200 Molecular Probes
mouse IgM HRP polyclonal donkey F(ab’)2 0.8 mg/mL 1:7000 JacksonImmuno
Alexa594 polyclonal goat IgG 2 mg/mL 1:1000 Invitrogen
R-PE polyclonal rat Ig 0.2 mg/mL 1:100 BD Biosciences
mouse IgG2a FITC polyclonal goat IgG 0.4 mg/mL 1:100 Abd Serotec
rat IgG,IgM HRP polyclonal goat IgG 0.8 mg/mL 1:1000 JacksonImmuno
Alexa594 polyclonal goat IgG 2 mg/mL 1:1000 Molecular Probes
rabbit IgG biotin polyclonal donkey IgG 1.1 mg/mL 1:1000 JacksonImmuno
Alexa568 polyclonal donkey IgG 2 mg/mL 1:1000 Invitrogen
human IgA,IgG,IgM biotin polyclonal goat F(ab’)2 1.2 mg/mL 1:1000 JacksonImmuno
HRP polyclonal goat IgG 0.8 mg/mL 1:7000 JacksonImmuno
R-PE polyclonal goat F(ab’)2 0.1mg/mL 1:150 SouthernBiotech
DyLight488 polyclonal goat IgG 1.5 mg/mL 1:150 JacksonImmuno
DyLight649 polyclonal goat IgG 1.5 mg/mL 1:150 JacksonImmuno
- polyclonal goat IgG 2.4 mg/mL - JacksonImmuno
human IgG HRP polyclonal goat IgG 0.8 mg/mL 1:7000 JacksonImmuno
DyLight488 polyclonal goat IgG 1.5 mg/mL 1:100 JacksonImmuno
R-PE polyclonal goat F(ab’)2 0.5 mg/mL 1:150 JacksonImmuno
DyLight649 polyclonal goat F(ab’)2 1.5 mg/mL 1:150 JacksonImmuno
human IgA biotin polyclonal goat F(ab’)2 1.2 mg/mL 1:1000 JacksonImmuno
DyLight488 polyclonal goat IgG 1.5 mg/mL 1:100 JacksonImmuno
R-PE polyclonal goat IgG 0.5 mg/mL 1:50 JacksonImmuno
PerCP polyclonal goat IgG 0.5 mg/mL 1:50 JacksonImmuno
human IgM HRP polyclonal goat IgG 0.8 mg/mL 1:7000 JacksonImmuno
DyLight 488 polyclonal goat IgG 1.5 mg/mL 1:100 JacksonImmuno
R-PE polyclonal donkey F(ab’)2 0.5 mg/mL 1:100 JacksonImmuno
DyLight649 polyclonal donkey F(ab’)2 1.5 mg/mL 1:100 JacksonImmuno
human IgG1 biotin 4E3 mouse IgG1 0.5 mg/mL 1:1000 SouthernBiotech
R-PE 4E3 mouse IgG1 0.1 mg/mL 1:1000 SouthernBiotech
human IgG2 biotin 31-7-4 mouse IgG1 0.5 mg/mL 1:1000 SouthernBiotech
R-PE 31-7-4 mouse IgG1 0.1 mg/mL 1:1000 SouthernBiotech
human IgG3 biotin HP6050 mouse IgG1 0.5 mg/mL 1:1000 SouthernBiotech
R-PE HP6050 mouse IgG1 0.1 mg/mL 1:1000 SouthernBiotech
human IgG4 biotin HP6025 mouse IgG1 0.5 mg/mL 1:1000 SouthernBiotech
R-PE HP6025 mouse IgG1 0.1 mg/mL 1:1000 SouthernBiotech
isotype control - polyclonal human IgG 11.2 mg/mL - Sigma Aldrich
isotype control - eBM2a mouse IgG2a - - eBioscience
isotype control - eB121-15F9 mouse IgM - - eBioscience
isotype control - polyclonal rabbit IgG - - Dako
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3.5.2 Serum screening
3.5.2.1 Cell-based assay by flow cytometry
Cell-bound recombinant protein antigens in native conformation were used to probe for reac-
tive autoantibodies in human serum. For each serum sample, TE671 cells expressing human
NF155 and human NF186, and also cells transfected with the empty vector were stained. The
3 cell lines (TE-RSV0, TE-NF155, TE-NF186) were plated at 200 000 cells per well. After
pelleting by centrifugation, the cells were stained with antibodies.
Initial experiments to set up a staining protocol utilized pan-NF mAbs (A12/18.1, A4/3.4) and
secondary detection antibodies conjugated to fluorescent molecules. The initial staining proto-
col was the following: 100 µL of 1:100 diluted primary antibody or 1:100 diluted human serum
was used to resuspend the cell pellet and this was incubated on ice for 1 h. Following 2 washes
with 200 µL PBS/1% FCS, 100 µL secondary detection antibody solution (1:200 anti-mouse-
Ig-PE (Dako, Eching, Germany) or 1:100 anti-human-IgG-DyLight488 (JacksonImmuno, New-
market, UK)) was applied and the cells were incubated on ice for 45 min. After 3 washes, the
cells were resuspended in 100 µL PBS with TO-PRO3 (1:4000; Invitrogen). The stained cells
were acquired on FACS Calibur (BD Biosciences), and the data was analyzed on FlowJo (Tree
Star Inc., Ashland, USA). The fluorescence intensity measured on the NF-expressing cells was
divided by the intensity measured on cells with the empty vector to normalize for background
staining.
The optimized protocol contained the following modifications: serum samples were diluted 1:50
in PBS/1% FCS and 100 µL was used to stain cells in each well, this was incubated for 1 h
on ice; after 2 washes with 200 µL PBS/1% FCS, 100 µL secondary antibody solution (1:150
anti-human-IgG-PE or 1:150 anti-human-Ig-PE, both from JacksonImmuno) was added and
incubated on ice for 35 min. Following 3 washes, the cells were again resuspended in PBS
with TO-PRO3 iodide for analysis as in the previous protocol. It was found to be important to
keep the cells cold during the entire procedure.
3.5.2.2 ELISA
Soluble recombinant human NF155 and NF186 were immobilized on a solid surface to be
displayed in random orientation for antibody detection. The optimized protocol was the fol-
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lowing: 5 µg/mL of human NF155 and NF186, rat NF155 (R&D Systems, Abingdon, UK), and
BSA (Serva) were used for coating in 0.1 M carbonate buffer at pH 9.5 (maxisorp) or 1 x PBS
(Ni-NTA) at 4 ◦C overnight. After washing with PBS, the plate was blocked with 200 µL of
PBS/0.05% Tween-20 (PBST) with 3% BSA (Serva) at 37 ◦C for 1 h. The plate was then washed
with PBST. To each well, 100 µL of sera diluted 1:100 or 0.2 µg/mL mAb (A4/3.4) in blocking
buffer was applied to wells coated with BSA, human NF155 and NF186 and rat NF155; this
was incubated for 1 h at 37 ◦C. After washing with PBST, 100 µL of anti-human-Ig-horseradish
peroxidase (HRP; 1:7000; JacksonImmuno) or anti-mouse-IgM-HRP (JacksonImmuno) was
added into each well and the plate was incubated at 37 ◦C for 30 min. After washing with
PBST, 100 µL of TMB solution (eBioscience) was added to each well and 50 µL of 2 N sulfuric
acid was used to stop the reaction once sufficient colour change was observed. The optical
density was measured at 450 nm, and the data was analyzed using Prism Graphpad (Graphpad
software, La Jolla, USA). For antigen crossreactivity experiments, human contactin-2 and hu-
man oligodendrocyte myelin glycoprotein (OMgp) (both from R&D systems) were incorporated
to the panel of test antigens used for screening.
3.5.2.3 Western blot
To screen human serum for NF reactivity by Western blot, we blotted NF155 and NF186 onto
polyvinylidene fluoride (PVDF) membrane, and stained each blot with a diluted serum sample.
In detail: 1 µg of each neurofascin and 3 µL of Protein Rainbow Marker (GE Healthcare, Munich,
Germany) were loaded for every 3 lanes on a 4-12% BIS-TRIS gel (Invitrogen). The gel was
subjected to electrophoresis at 200 V for 1 h. Hybond-P PVDF-membrane (GE Healthcare)
was cut to the size of the gel,activated by methanol, washed with water and then incubated
in cold transfer buffer (20x NuPAGE transfer buffer, Invitrogen). When the gel electrophoresis
was completed, the ’blot sandwich’ was built and placed between the electrode-plates of a
semi-dry transfer apparatus. The ’blot sandwich’ from cathode to anode consisted of 3 sheets
of 3 mm Whatman filter paper pre-soaked in transfer buffer, the gel on top of the membrane,
and then another 3 sheets of pre-soaked filter paper. The semi-dry transfer set at 0.8 mA/cm2
for 90 min. Afterwards, the membrane was cut into strips where each strip contain the protein
marker, NF155, and NF186. These strips were blocked in 5% skim milk in PBST for 1 h at room
temperature. After washing with PBST, each strip was incubated in diluted human serum (1:400
in blocking solution) overnight at 4 ◦C on a shaker. These strips were washed with PBST for 1 h
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at room temperature, and anti-human-Ig-HRP (1:7000; JacksonImmuno) was applied for 1 h at
room temperature on a shaker. After washing with PBST, enzymatic chemiluminescence (ECL)
solution was applied for 1 min. The ECL solution was a mixture of 10 mL ECL-A (0.25% (w/v)
luminol in 1M Tris/HCl), 100 µL ECL-B (0.11% (w/v) para-hydroxycoumarin acid in DMSO), and
3.1 µL of 30% H2O2. Then the strip was exposed onto autoradiography film (GE Healthcare)
for 3 sec to 1 min. Visual analysis was done on a lightbox for presence of bands where each
neurofascin isoform was blotted.
3.5.3 Epitope mapping by cell-based assay
TE671 cell lines stably transfected with truncated forms of NF155 or NF186 were used to elu-
cidate the immunogenic region within the multi-domain protein. The truncation mutants were
made to express (1) immunoglobulin-like (Ig)1-Ig2-Ig3-Ig4-Ig5-Ig6 domains, (2) fibronectin type
III (Fn)1-Fn2 domains, (3) Fn3-Fn4 domains, (4) Fn3 domain, (5) Fn4-Mucin-Fn5 domains, and
(6) Mucin-Fn5 domains. To monitor the level of transgene expression, each truncated version
of NF was tagged with super-GFP (sGFP) in the cytoplasmic region. NF155 or NF186 reactive
samples identified by flow cytometry were diluted 1:100 in PBS/1% FCS for staining. Secondary
anti-human-Ig conjugated to Dylight649 (1:200, JacksonImmuno) was used for detection. The
fluorescence intensity of sGFP was plotted against Dylight649, and the staining was scored
positive if (1) the mean fluorescence intensity in the FL4-channel (for Dylight649) was higher
than that measured on control cells and (2) there was a strong direct correlation between the
level of sGFP expression and the amount of staining observed.
3.5.4 Epitope mapping by Western blot
Recombinant truncated forms of NF155 and NF186 expressed in Rosetta E. coli cells were: (1)
Ig1-Ig2-Ig3-Ig4, (2) Ig5-Ig6-Fn1-Fn2, (3) Fn3-Fn4, and (4) Fn4-Mucin-Fn5. These 4 fragments
along with the complete NF155 and NF186 were blotted onto PVDF membrane and probed
with diluted serum as described in Section 3.5.2.3.
3.5.5 Isotyping
For isotyping of NF reactivity by flow cytometry or ELISA, the procedures described in Sec-
tions 3.5.2.1 and 3.5.2.2 were modified at the step of primary human antibody detection. In-
CHAPTER 3. MATERIAL AND METHODS 45
stead of using anti-human-Ig conjugated with either PE or HRP for detection of all antibod-
ies indiscriminantly, the following secondary antibodies were used: anti-human-IgG1, anti-
human-IgG2, anti-human-IgG3, anti-human-IgG4, anti-human-IgM, or anti-human-IgA (Jack-
sonImmuno, SouthernBiotech).
3.5.6 Serial dilution
Serum samples were diluted 1:100, 1:500, 1:1000, and 1:10 000 to probe for reactivity using
the same procedure as described in Sections 3.5.2.1 and 3.5.2.2
3.5.7 Immunohistochemistry
Fresh rat spinal cord was embedded in tissue freezing medium (Leica, Wetzlar, Germany) and
10 µm thick longitudinal sections were cut using a cryotome. The tissue was stored at -20 ◦C.
Prior to staining, sections were fixed for 7 min in ice cold methanol and blocked with goat IgG
(Sigma-Aldrich) diluted in antibody diluent (Dako) for 3 h at room temperature. Human serum
was diluted 1:100 and purified human antibodies were diluted to 2 µg/mL in PBS/10% FBS,
and applied to a tissue section for overnight incubation at 4 ◦C. ivIG (Intratect; Biotest Pharma,
Dreieich, Germany) was adopted as healthy control immunoglobulin preparation. After PBS
wash, anti-human-IgG-Alexa488 secondary antibody (1:100; Invitrogen) and DAPI (1:1000
Thermo Scientific) were applied. Subsequently Caspr-specific rabbit serum antibody (1:1000;
Peles et al. (1997)) was incubated with the tissue sections for 1 h at room temperature. The
sections were washed and secondary antibody (anti-rabbit-IgG-Alexa594, 1:1000; Invitrogen)
was added to the section for 45 min at room temperature. They were then washed and mounted
with coverslips using fluoromount (Invitrogen).
3.5.8 Antibody purification by antibody-antigen affinity chromatography
Recombinant neurofascin (human NF155, NF186, or rat NF155-NS0) was covalently conju-
gated to N-hydroxysuccinimide (NHS)-activated sepharose (GE Healthcare, Munich, Germany)
at 0.5 mg/mL according to the protocol provided by the manufacturer. The NF-conjugated ma-
trix was then packed into a column bed (Sigma-Aldrich) and stored in PBS with 10 mM NaN3
(Merck, Darmstadt, Germany) and 0.1 mM PMSF (Sigma-Aldrich) at 4 ◦C. Human samples
were stored in -20 ◦C. Sample preparation was as follows: centrifugation at 4000 rpm for 10
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min, filtration through a 0.22 µm Stericup (Millipore, Schwalbach, Germany), 1:1 dilution with
PBS and the pH was adjusted to 7.0. NaN3 and PMSF were added to final concentrations of 10
mM and 0.1 mM respectively. The column was loaded with the sample at 4 ◦C. After loading,
elution was done at an FPLC setup (Pharmacia, Uppsala, Sweden) at pH 5, pH 4, pH 3, and pH
11, while bringing the pH up to neutral in between each pH step. The buffers used were: PBS
at pH 7.2, 100 mM citrate with 150 mM NaCl at pH 5, 100 mM acetate with 150 mM NaCl at pH
4, 100 mM glycine with 150 mM NaCl at pH 2.7, and 100 mM ethanolamine with 150 mM NaCl
at pH 11.2. Elution was monitored by absorbance at 280 nm. The eluted fractions were con-
centrated and dialyzed with PBS using Amicon Ultra centrifugation filters (Millipore) according
to the protocol provided by the manufacturer. ivIG (Intratect; Biotest Pharma, Dreieich, Ger-
many) was adopted as healthy control immunoglobulin for these experiments. A sample of
each fraction was analyzed on a reducing SDS-PAGE gel for visualization of antibodies and
contaminants.
3.5.9 Antibody quantification by ELISA
Human antibodies (purified Abs, serum, cerebrospinal fluid) were quantified by ELISA. In detail,
affinity-purified anti-human-IgG,IgM,IgA polyclonal goat IgG (JacksonImmuno) was coated on
a maxisorp plate (Nunc) at 2 µg/mL in 0.1 M carbonate buffer (pH 9) at 4 ◦C overnight. After
blocking with 3% BSA in PBST, 100 µL of diluted antibody samples may be added. Serum was
normally diluted 1:1000 000, and then further diluted 1:10 and 1:100. Purified antibodies were
diluted 1:1000, and then further diluted 1:10, 1:100, 1:1000. CSF samples were diluted 1:1000,
and then 1:100, 1:1000, 1:10 000. Protein concentration estimates were made using a standard
curve of known concentrations of intravenous immunoglobulin (ivIG; pooled human antibodies).
The ivIG standard curve was the following (in pg/mL): 0, 8, 16, 32, 64, 128, 256, 512, 1024,
2048, 4096, and 8192. The diluted antibody samples and ivIG solutions were incubated for 1
h at 37 ◦C. Secondary anti-human-IgG,IgM,IgA polyclonal goat IgG conjugated to horseradish
peroxidase (JacksonImmuno) was diluted 1:7000 and applied to the ELISA plate for 30 min at
37 ◦C. Afterwards, TMB substrate solution (eBioscience) was added, followed by 2 N sulfuric
acid to stop the colormetric reaction, and then optical density at 450 nm was measured. The
data was analyzed on Prism Graphpad (Graphpad software, La Jolla, USA) and estimates of
antibody concentration in a complex protein mixture was inferred from the standard curve.
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3.6 Experimental autoimmune neuritis animal experiments
P2-peptide (AA 53-78; Uyemura et al. (1982)) was synthesized by the Core Facility in the Max
Planck Institute of Biochemistry (Martinsried, Germany). To induce EAN, Lewis rats were im-
munized subcutaneously on both hind limbs with 100 µg of P2-peptide emulsified in Complete
Freund’s Adjuvant (CFA; Difco, Lawrence, USA). Clinical scores and body weight were moni-
tored daily. Clinical scores were evaluated as follows: 0 = normal; 0.5 = loss of tail tonus; 1 =
tail paralysis; 2 = gait disturbance; 3 = hind-limb paralysis. Upon initial signs of clinical disease
approximately 2 weeks after peptide immunization, anti-NF antibodies (A12/18.1, A4/3.4) or
their respective isotype controls (mouse IgG2a, mouse IgM; eBioscience) were injected intra-
venously into the EAN rat at 500 µg per rat. The animals were followed until full recovery was
seen in all four groups, and then they were sacrificed. (Dr. Naoto Kawakami, from the Institute
of Clinical Neuroimmunology, performed the animal experiments and provided the information
for this text)

Chapter 4
Results
CHAPTER 4. RESULTS 50
4.1 Cloning and recombinant expression of neurofascin
4.1.1 Construction of expression plasmids
The complete DNA templates of human NF155 and human NF186 were constructed piecewise
using human brain RNA and a commercially available cDNA clone. All other constructs were
derived from these DNA templates.
4.1.1.1 Complete transmembrane form of NF155 and NF186
All self-designed oligonucleotide primers were produced by Metabion (Martinsried, Germany).
Primers were designed according to the following criteria: annealing temperature near 60 ◦C
(summation of each A/T=2 ◦C and C/G=4 ◦C), 20 nt in length, and C/G at the 3’ end.
The complete DNA of human NF155 and NF186 were generated stepwise according to the
cloning strategy devised by Dr. Klaus Dornmair. First, cDNA from RNA of human brain was
prepared with RT-primers specific to the cytosolic region (primer-1; Table 3.1) and to the third
immunoglobulin domain (primer-2). Next three fragments were amplified by PCR: Fragment 1
that spans the signal sequence and immunoglobulin-like domains (Ig)-1 and -2 using primer-3
and -4, Fragment 2 that spans fibronectin type III domains (Fn)-3 and -4 and the transmembrane
domain with primer-5 and -7, and Fragment 3 that spans Fn-4,Mucin,Fn-5 and the transmem-
brane domain using primer-6 and -7. Fragment 1 is common to both isoforms while Fragment
2 is NF155-specific and Fragment 3 is NF186-specific. For the cDNA fragment containing Ig-
3,-4,-5,-6 and Fn-1,-2 domains that are common to both isoforms, it was excised from cDNA
clone IRAKp961P2270Q (GenomeCube, Nottingham, UK) using restriction sites HindIII and
Avr II. (Figure 4.1)
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RT-P2 RT-P1
HindIII AvrII
HindIII AvrII
Figure 4.1: Amplification and digestion for fragments of NF155 and NF186: NF155 and
NF186 both contain a signal sequence, 6 immunoglobulin-like domains (Ig; black), fibronectin
type-III domains (Fn; white), transmembrane domain (TM) and cytoplasmic region (Cyt). NF186
has a mucin domain. Primers used for amplication are indicated with red arrows (P = primer;
RT = reverse transcription). The region covered by the fragment excised using HindIII and Avr II
restriction enzymes from the cDNA clone IRAKp961P2270Q is indicated.
To assemble the fragments, pcDNA6.1v5 His C (Invitrogen) was used as a surrogate vector.
First, the vector and Fragment 1 were cut withEcoRI andHindIII, and they were ligated together.
Next this ligation product was cut with HindIII and NheI, and ligated with the cDNA fragment
digested with HindIII and Avr II. This plasmid containing both fragments was cut with BsimI and
BglII, and either Fragment 2 or Fragment 3 was inserted, producing essentially the cDNAs of
the entire NF155 and NF186 (Figure 4.2). Both full-length NFs were excised from the pcDNA
plasmid using SalI and BglII, and ligated into a plasmid vector appropriate for each expression
system used. For each construct, full-length sequencing was done to confirm the sequence
identity. For cell surface expression of the full-length neurofascins on TE671 cell line, the full
NF cDNA was inserted into pRSV5neo (Long et al., 1991) using SalI and BamHI sites (example
in Figure 4.3). This cloning work was done together with Joachim Malotka.
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RT-PCR
DNA gels
Fragment 3
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Figure 4.2: Schematic of NF155 and NF186 cloning strategy: Left panel: DNA gels used
in the cloning process. cDNA generated from theRT-PCR reaction was reamplified by PCR
for Fragment 1, Fragment 3-155 and Fragment 3-186. Fragment 2 was cut from the RZPD
clone plasmid using restriction enzymes, and it was purified from the resulting mixture of DNA
fragments by gel separation and subsequent purification from the gel. TOPO cloning was used
to further amplify the scarce material obtained from PCR amplification of Fragment 1, Fragment
3-155 and Fragment 3-186. Right panel: Fragment 1, Fragment 2, and Fragment 3-155/186
were assembled using pCDNA6V5-His C vector. Fragment 1 and Fragment 2 were joined
through the HindIII restriction site, Fragment 2 and Fragment 3 were joined through the BsimI
site. The neurofascin gene insert was in reverse orientation in the pcDNA vector; it was cut out
using SalI and BglII to be subcloned into an appropriate expression vector.
HindIII (8512) SalI (14)
HindIII (751)
BsimI (2477)
pRSV5neo - NF186TM
AmpR
NeoR
HindIII (5604)
SV40 prom
5’ LTR of RSV
Figure 4.3: pRSV5neo with transmembrane NF186: NF186TM was cut from pcDNA vector
with SalI and BglII and ligated into pRSV5neo vector digested with SalI and BamHI in correct
orientation for mammalian expression using the rous sarcoma virus (RSV) promoter within the
5’ long terminal repeat (LTR). There are also a neomycin resistence gene (NeoR), simian virus
promoter (SV40 prom), and an ampicillin resistence gene (AmpR). Vector map was generated
on VectorNTI (Life Technologies, USA)
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4.1.1.2 Soluble form of NF155 and NF186
For secreted soluble NF155 and NF186, primer-7 was replaced by primer-8 to generate new
Fragment 2 (for NF155) and Fragment 3 (for NF186) in which the transmembrane domain was
substituted with a polyhistidine tag. They were assembled with Fragment 1 and the excised
cDNA fragment as described in Section 4.1.1.1. For soluble NF production in HEK293-EBNA1
(293E) cells, both NF constructs containing the polyhistidine tag were inserted into pTT5 di-
gested with PmeI and BamHI by first making the SalI site of the insert blunt-ended and then
cutting with BglII.
4.1.1.3 Transmembrane form of truncated NF variants
We produced six truncated variants of NF155 and NF186 that were fused to superGFP (sGFP)
at the C-terminus for cell surface expression. First, we constructed a cassette vector with sGFP
inserted into plasmid pRSV5neo by PCR-amplifying sGFP from another plasmid using primer-
15,-16. We cut this PCR product and pRSV5neo with XbaI, ligated them, and identified a clone
containing the insert in the correct orientation for expression. The pRSV5neo vector containing
sGFP was referred to as pRSV5neo-sGFP (Figure 4.4).
Figure 4.4: Schematic of pRSV5neo-sGFP cassette vector: The vector contains the RSV
promoter driving the sGFP (or sGFP-fusion protein) expression, the polyA sequence of simian
virus 40 (SV40 polyA), neomycin resistence (NeoR), origin of replication and promoter of
SV40 (SV40 prom/ori), ampicillin resistence (AmpR), origin of replication (pBR322 ori), and
the cloning sites SalI and ClaI. Vector map generated on DNADynamo (BlueTractor, UK).
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Figure 4.5: Schematic of sGFP fusion truncated NF variants for cell surface expression:
Sig = signal sequence; Ig = immunoglobulin-like domain; Fn = fibronectin type-III domain; TM
= transmembrane domain; sGFP = super GFP. Details of the fragments in text (as numbered).
To generate the truncated NF constructs, a combination of restriction enzymes and overlap-
extension-PCR amplification (Heckman and Pease, 2007) was used. Each construct contained
a signal sequence and a transmembrane domain to ensure cell surface expression, and they
were fused to sGFP in the cytosolic region. (Figure 4.5)
(1) For NF-Ig construct spanning the six Ig-domains, a fragment with the signal sequence and
the six Ig-domains was excised from the complete NF155 construct using SalI and NheI. The
transmembrane domain fragment was PCR-amplified with primer-17 and -18. The PCR product
and the pRSV5neo-sGFP vector were both digested with SalI and ClaI, and ligated together.
The ligation product was then cut with SalI and NheI, and the fragment with the Ig-domains
was inserted. (2) For NF-Fn1Fn2 construct covering Fn1-Fn2 domains, three PCR products
were produced to separately cover the signal sequence, the Fn1-Fn2 domains, and the trans-
membrane domain, using primer-19,-20, primer-21,-22, and primer-23,-18 respectively. The
Fn1-Fn2 domains and transmembrane domain were ligated through a MroI site. This ligation
product was PCR-amplified, and then joined with the signal sequence fragment by overlap-
extension PCR. The PCR product was inserted into the pRSV5neo-sGFP vector through SalI
and ClaI restriction sites, as it was for the following inserts described. (3) The NF-Fn3Fn4
construct required overlap-extension PCR to join the signal sequence PCR product (primer-
19 and -24) and the Fn3-Fn4 domains, and transmembrane domains PCR product (primer-25
and -18). (4) The NF-Fn4MucFn5 insert also required overlap-extension PCR to join the PCR
product for the signal sequence (primer-19 and -26) and the PCR product for Fn4-Muc-Fn5,
and transmembrane domains (primer-27 and -18). (5) The NF155-specific NF-Fn3 fragment
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was produced by joining 3 PCR products: the signal sequence (primer-19 and -24), the Fn3
domain (primer-25 and -28), and the transmembrane domain (primer-29 and -18). The Fn3
domain fragment was joined to the transmembrane domain though a BstZ17I restriction site,
and this ligation product was joined with the signal sequence by overlap-extension PCR. (6)
For the fragment NF-MucFn5, two PCR fragments were joined by overlap-extension PCR: the
signal sequence fragment (primer-19 and -30) and the fragment containing Muc-Fn5 and the
transmembrane domain (primer-31 and -18).
4.1.1.4 Soluble form of truncated NF variants
For soluble truncated NF variants, we made four constructs containing C-terminus polyHis-tags
by PCR amplification using the complete NF constructs as template: 1) Ig1-Ig2-Ig3-Ig4 using
primer-9 and -10; 2) Ig5-Ig6-Fn-1-Fn2 using primer-11 and -12; 3) Fn3-Fn4 using primer-13 and
-8; 4) Fn4-Muc-Fn5 using primer-14 and -8 (Figure 4.6). These inserts were all digested with
ScaI and BglII, and the vector was digested with NheI, made blunt-ended, and subsequently
digested withBamHI. The four ligated pET21c(+) constructs were then transformed into Rosetta
competent cells for protein production.
Ig1 Ig2 Ig3 Ig4
Sig
6xHis
Ig5 Ig6 Fn1 Fn2 6xHis
Fn3 Fn4 6xHis
Fn4 Mucin Fn5 6xHis
(1) (3) 
(2) (4) 
Figure 4.6: Schematic of soluble truncated NFs: Sig = signal sequence; Ig =
immunoglobulin-like domain; Fn = fibronectin type-III domain; TM = transmembrane domain;
sGFP = super GFP; 6xHis = polyhistidine tag. Details of the fragments in text (as numbered).
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4.1.1.5 List of plasmids generated for this study
Table 4.1: Plasmid list
Vector Insert Expression Intended host cell line
1 pRSV5neo - - TE671, HeLa
2 pRSV5neo NF155TM cell surface TE671, HeLa
3 pRSV5neo NF186TM cell surface TE671, HeLa
4 pRSV5neo NF155sol soluble HEK293
5 pRSV5neo NF186sol soluble HEK293
6 pRSV5neo sGFP cytosolic TE671
7 pRSV5neo 6Ig-sGFP cell surface TE671
8 pRSV5neo Fn1Fn2-sGFP cell surface TE671
9 pRSV5neo Fn3Fn4-sGFP cell surface TE671
10 pRSV5neo Fn3-sGFP cell surface TE671
11 pRSV5neo FN4MucFn5-sGFP cell surface TE671
12 pRSV5neo MucFn5-sGFP cell surface TE671
13 pTT5 NF155sol soluble HEK293-EBNA
14 pTT5 NF186sol soluble HEK293-EBNA
15 pET21c(+) Ig1Ig2Ig3Ig4 soluble Rosetta E. coli
16 pET21c(+) Ig5Ig6Fn1Fn2 soluble Rosetta E. coli
17 pET21c(+) Fn3Fn4 soluble Rosetta E. coli
18 pET21c(+) Fn4MucFn5 soluble Rosetta E. coli
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4.1.2 Recombinant expression of complete NFs and truncated variants
4.1.2.1 Cell lines expressing complete NF155 and NF186
TE671 human rhabdomyosarcoma cells were transfected with linearized pRSV5neo-NF155
and -NF186 to produce cell lines with stable expression of the gene of interest. Individual
colonies were picked from single cells that were successfully transfected and that had expanded
during the subsequent two weeks of incubation. The expression profiles of the cell lines with
the best expression that were employed for antibody detection assays are shown in Figure 4.7
as compared to cells transfected with only the mock vector.
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Figure 4.7: Expression profile of TE671 cells transfected with NF155 and NF186: TE671
cells transfected with the pRSV5neo vector only (black), with pRSV5neo-NF155 (blue), and
with pRSV5neo-NF186 (orange). The 3 cell lines were stained with anti-pan-NF mAb A12/18.1,
which recognizes the Fn4 domain that is present in both isoforms of NF.
4.1.2.2 Cell lines expressing truncated NF variants
TE671 cells were also transfected with linearized pRSV5neo-sGFP containing 6Ig, Fn1-Fn2,
Fn3-Fn4, Fn3, Fn4-Muc-Fn5 and Muc-Fn5 to produce cell lines with stable transgene expres-
sion as indicated by the intensity of sGFP fluorescence. Individual colonies were picked and
individually expanded. All the cell lines were analyzed by flow cytometry to evaluate expression
levels. The expression profiles of the cell lines used for epitope mapping are shown in Figure
4.8.
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Figure 4.8: Expression profile of sGFP fusion truncated NF variants compared to TE671
mock transfected cells: (from left to right) sGFP only, 6Ig, Fn1-Fn2, Fn3-Fn4, Fn3, Fn4-Muc-
Fn5 and Muc-Fn5.
4.1.2.3 Soluble complete NF155 and NF186
Soluble complete NF155 and NF186 were produced in HEK293-EBNA cells by transient trans-
fection. Typically from 1 L of cell culture, up to 20 mg of protein could be purified from the
supernatant by Ni-NTA chromatography through the His-tag. Purity of the eluted fractions of
NF155 and NF186, as well as recognition by pan-NF mAb (A12/18.1) and anti-His-tag mAb are
shown in Figure 4.9.
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Figure 4.9: Soluble NF155 and NF186 by SDS-PAGE and Western blot: (Left) Coomassie
blue and silver stained SDS-PAGE show NF155 and NF186 at around 150 kDa and just below
225kDa, and the purity achieved for the preparation; (Right) Western blots detected with anti-
bodies against NF (using A12/18.1) and the His-tag showed bands for NF155 (left band) and
NF186 (right band) at the expected positions.
CD spectroscopy analysis of protein conformation
CD spectroscopy was performed to analyze the conformation of the soluble neurofascins. A CD
spectra between 250-195 nm was measured for each protein. For both NF155 and NF186, the
spectra were dominated by the presence of beta-sheet structure, consistent with the structure
of neurofascins predicted by bioinformatics tool NextProt (www.nextprot.org).
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Figure 4.10: CD-Spectra of soluble NF155 and NF186: (Left) NF155; (Middle) NF186; (Right)
Reference absorption graphs show the absorbance curve of alpha helices, beta sheets, and
random coils (adapted from lecture notes of Dr. Ramy Farid, USA).
CHAPTER 4. RESULTS 60
4.1.2.4 Soluble truncated NF variants
Soluble truncated NF variants were produced in Rosetta E. Coli cells and found in the inclusion
bodies. The His-tagged truncated NFs (1) Ig1-Ig2-Ig3-Ig4, (2) Ig5-Ig6-Fn1-Fn2, (3) Fn3-Fn4,
and (4) Fn4-Muc-Fn5 were solublized and then purified using Ni-NTA chromatography. Their
sizes were visualized by SDS-PAGE and identified using anti-His-tag antibody by Western blot
(Figure 4.11).
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Figure 4.11: Soluble NF truncation variants by SDS-PAGE and Western blot: (Left) A
Coomassie blue stained SDS-PAGE gel of protein preparation; (Right) Western blot using an
antibody against the His-tag shows bands for all 4 fragments at the expected positions. Lane
3 shows the Fn3-Fn4 fragment in the upper band and a degradation product of the fragment in
the lower band.
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4.2 Establishment of anti-NF antibody detection assays
Three assays were established to detect anti-neurofascin autoantibodies in human serum: cell-
based assay by flow cytometry, ELISA, and Western blot. Using cell-based assay, we detected
antibodies against NF in its the native conformation. By ELISA, we could detect antibodies
against NF that was not completely denatured, but it was also not in its native conformation.
With Western blot, we detected antibodies against continuous epitopes of NF.
4.2.1 Cell-based assay by flow cytometry
Detection of NF-specific antibodies on NF-transfected cells relied on the ability to distinguish
the signal specific to the over-expressed NF on the cell surface from the background signal
coming from antibodies staining something inherently present on the surface of the TE671 cells.
With every serum sample, we stained the NF-overexpressing cell lines (TE-NF155 and TE-
NF186) and cells harbouring only the empty vector (TE-RSV0). The signals (mean fluorescence
intensity; MFI) measured on TE-NF155 and TE-NF186 were then divided by the signal from TE-
RSV0 to normalize for background staining. A negative control staining should give a MFI ratio
of approximately 1.
The first step was to make the three cell lines comparable. Initially, the background signal of the
cell lines did not give an MFI ratio of 1, which means that only very strong signals were detected
and weak signals were masked. We cultured the three cell lines in the same medium with
supplements and antibiotic selection, passaged them together, and used new cell culture bottles
every time to avoid influence of residual protein left on the bottle surface after trypsinization.
After several passages, the cell lines showed comparable background signal, then they could
be used for screening (Figure 4.12 A).
The serum samples were initially diluted 1:100 in PBS/1% FBS and a FITC-conjugated anti-
human IgG secondary antibody was used for detection. Optimization of this staining protocol
was complicated by the lack of anti-NF Ab positive serum samples. We screened 80 serum
samples and found one to with NF186 reactivity. We used this positive sample to optimize the
screening procedure. The modifications included: dilution of serum 1:50 and detection with
anti-human-IgG or anti-human-Ig secondary antibody conjugated with PE (Figure 4.12 B). The
established protocol is outlined in Section 3.5.2.1.
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Figure 4.12: Optimization of cell-based assay by flow cytometry: TE-RSV0 (black, filled),
TE-NF155 (blue line), and TE-NF186 (orange line) stained with only the secondary anti-human-
IgG antibody (A) before and after optimization. TE-RSV0 and TE-NF186 were stained with
anti-NF186 reactive patient serum and detected by anti-human-IgG conjugated with FITC and
PE (B). The cell lines became comparable for background signal and signal-to-noise ratio was
improved after optimization.
4.2.2 ELISA
For ELISA detection of NF-specific autoantibodies in human sera, we considered how the anti-
gen was displayed, the optimization of signal-to-noise ratio, and the reproducibility of the re-
sults.
To choose a suitable solid support for the assay, we compared maxisorp plates and nickel-
chelate (Ni-NTA) coated plates. While maxisorp plates involve mainly hydrophilic binding of
the glycosylated protein antigen, Ni-NTA coated plates utilize C-terminus His-tag to bind the
antigen, thus theoretically conferring orientation to the displayed antigen. We compared the
utility of the two different supports using monoclonal anti-NF antibodies, serum from rats im-
munized with human NF155, and serum from a human donor. We noted that although pattern of
reactivity to human NF155 and NF186, and rat NF155 in each staining was essentially identical
in both types of plates, the signals observed were consistently stronger on the maxisorp plates
(Figure 4.13 B and C). In addition, reproducibility using maxisorp plates was superior com-
pared to Ni-NTA plates. This could be due to leakage of the antigen from the Ni-NTA beads
and interference from unknown factors present in the serum that produce an inconsistent level
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of background. An additional consideration for our choice to use maxisorp plates for screening
of serum samples was the economy of the procedure.
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Figure 4.13: Optimization of the ELISA protocol: Level of reactivity of A4/3.4 mAb towards
hNF155 coated at 1 µg/mL, 3 µg/mL and 10 µg/mL is shown (A). Reactivities of A4/3.4 mAb
(0.1µg/mL), serum from a rat immunized with HEK NF155 (1:1000), and control human serum
(1:100) against ratNF155-NS0, hNF155 and hNF186 from HEK cells, and negative control (BSA
for maxisorp plates, PR3 for Ni-NTA plates) were compared between maxisorp plates (B) and
Ni-NTA plates at 3 µg/mL(C). ELISA reactivity is shown here as the raw OD450 value.
Sensitivity of the assay was essential to the screening protocol. We coated maxisorp plates with
protein antigen at concentrations of 1, 3, and 10 µg/mL and then found the optimal concentration
for antigen coating to be between 3 and 10 µg/mL (Figure 4.13 A). So we subsequently tested
ELISA reactivity at 5 µg/mL. In addition, we tested human serum samples diluted 1:50, 1:100,
and 1:400, and found that 1:100 dilution gives the best signal-to-noise ratio. The optimized
protocol that was used for serum screening is described in Section 3.5.2.2.
4.2.2.1 ratNF155-NS0 is not a specific antigen to detect anti-NF reactivity
We also compared the utility of human NF155 and NF186 (self-generated) with rat NF155
(commercially available from R&D Systems) since ratNF155 was used as the antigen to de-
tect human antibodies to NF in previous studies (Mathey et al., 2007; Pruess et al., 2011).
RatNF155-NS0 was produced in NS0 murine myeloma cells while the human NFs were pro-
duced in HEK293 cells.
We found that while in total only very few donors showed low reactivity to HEK293-produced hu-
man NF155 and NF186 (Figure 4.23, ELISA screening of serum from MS patients and controls
shown), virtually all donors of the same cohort showed some response against ratNF155-NS0.
To investigate this large discrepency, we affinity-purified antibodies from four RR-MS donors
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using a ratNF155-NS0-conjugated column. With these purified antibodies, we probed for reac-
tivity against HEK293-EBNA-derived NF155 and NF186, ratNF155-NS0, and irrelevant NS0-
derived antigens: human contactin-2/TAG-1 and human OMgp. We found by ELISA that the
affinity-purified anti-ratNF155-NS0 antibodies did not bind NF155 and NF186, but recognized
the irrelevant NS0-derived antigens. By Western blot, a faint HEK293-derived NF155 band
was detected along with NS0-derived antigens, signifying that a small proportion of the purified
antibodies indeed recognize neurofascin. This was seen with all four donors (one example
shown in Figure 4.14 B and C). The mAb A4/3.4 recognized ratNF155-NS0 along with NF155
and NF186, and as expected, not contactin-2 or OMgp (Figure 4.14 B). Thus, we show that
although the ratNF155-NS0 was detected by some antibodies to NF, it was also recognized by
other Igs that were not NF-specific.
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Figure 4.14: ratNF155-NS0 was not a specific antigen to detect antibodies to human neu-
rofascin in human serum: Serum screening by ELISA using ratNF155-NS0 (A) included
samples from patients with MS (n=225), CIS (n=5), ALS (n=52), and controls OND (n=55),
HC (n=77). The delta OD (response to ratNF155-NS0 minus BSA reactivity) is shown. Most
of the patients and control donors show a response against this antigen. The mean of each
group is shown. Antibodies purified over rat NF155-NS0 conjugated column were tested by (B)
ELISA and (C) Western blot for reactivity against HEK293-EBNA derived NF155 and NF186,
ratNF155-NS0, and unrelated NS0-derived antigens: human contactin-2/TAG-1 (hTAG1) and
human oligodendrocyte myelin glycoprotein (hOMgp). The number above each lane in (C)
corresponds to the antigen with the same number in (B). Anti-pan-NF mAb (A4/3.4) was also
tested by ELISA and recognized NF155, NF186 and ratNF155-NS0 (B).
4.2.3 Western blot
The protocol for NF-specific antibody detection by Western blot is described in Section 3.5.2.3.
The procedure used was essentially the standard protocol for immunoblots. A drawback to
this approach was the high background signal observed when diluted serum was incubated
with the blotted membrane, which confounded our ability to detect an NF-specific signal. The
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advantage of performing Western blots is that we knew exactly where the NF-specific signal
should be in relation to the molecular weight ladder. For screening, we diluted human serum
1:400 in a blocking buffer (5% skim milk in PBST; filtered). Example blots are shown in Figure
4.24.
4.2.4 Reactivity of pan-NFmonoclonal antibodies andNF155-specific rabbit serum
in the assays
The three anti-NF antibody detection assays were tested using pan-NF mouse monoclonal an-
tibodies (A4/3.4 and A12/18.1) and rabbit serum that was generated against a peptide specific
to NF155. The mouse mAb A4/3.4 recognized both NF155 and NF186 strongly by flow cytom-
etry, ELISA and Western blot (Figure 4.15 A). The other mouse mAb A12/18.1 recognized both
isoforms strongly by flow cytometry, only the NF186 and hardly the NF155 by ELISA, and only
the NF186 by Western blot (Figure 4.15 B). The rabbit serum was unreactive to the NFs by
flow cytometry, but was strongly reactive to NF155 by ELISA. By immunohistochemistry using
longitudinally cut spinal cord sections, antibodies purified from the rabbit serum stained para-
nodes, where NF155 was located, and the A12/18.1 stained nodes, where NF186 was found
(Figure 4.15 C).
We further analyzed the specificity of the mAbs using truncation variants of NF155 and NF186
by Western blot (Figure 4.15 A and B right) and flow cytometry (Figure 4.16 B). We did not
detect reactivity by Western blot nor by flow cytometry with A4/3.4 using truncation variants.
With A12/18.1, we saw strong reactivity to Fn3-Fn4 (NF155 specific fragment) and also its
degradation product by Western blot, and by flow cytometry reactivity to Fn3-Fn4 and Fn4-
Muc-Fn5 fragments. Considering that A12/18.1 recognized both isoforms by flow cytometry,
evidence would indicate that the reactivity was directed to the Fn4 domain, which was common
to both isoforms.
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Figure 4.15: Reactivity of pan-NF mAbs and NF155-specific rabbit serum in the assays:
Reactivity of mAbs A4/3.4 (A) and A12/18.1 (B), and rabbit serum (C) by flow cytometry (left),
ELISA (middle), Western blot (right; upper 2 panels), immunohistochemistry on longitudinally
cut spinal cord section (right; lower panel). Flow cytometry results are depicted in histograms
for antibody staining intensity. ELISA results are shown as ∆OD450. The section was stained
with antibodies purified from the rabbit serum (red) and A12/18.1 (green).Serial dilution (in
ng/mL: 1000, 500, 250, 125, 75, 38.5, 18.25) was done for mAbs by flow cytometry and for all
three antibodies by ELISA. The antigens employed in Western blot analysis are shown in a blot
using anti-His tag antibody (D): complete extracellular regions of (1) hNF155 and (2) hNF186
produced in HEK293 cells, and truncated variants (3) Ig1-Ig2-Ig3-Ig4, (4) Ig5-Ig6-Fn1-Fn2, (5)
Fn3-Fn4, and (6) Fn4-Muc-Fn5 produced in E. coli.
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Figure 4.16: Domain specificity of pan-NF mAbs by flow cytometry: (A) A scheme of the
extracellular domains of NF155 and NF186 are shown. The six Ig-like domains and fibronectin
domains 1, 2 are common between the two isoforms. NF155 has Fn3 before Fn4 while Fn186
lacks the Fn3, has Fn4 and additionally a Mucin domain and Fn5 domain. (B) The reactivities
of the two mAbs (A4/3.4 and A12/18.1) to each truncation variant are shown next to a scheme
depicting each truncated NF variant.
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4.3 Neurofascin-specific autoantibodies inGuillain-Barré syndrome
and chronic inflammatory demyelinating polyneuropathy
In this study, we asked if anti-NF antibodies are present in serum of patients with peripheral
neuropathies. We screened serum samples from patients with different variants of inflammatory
neuropathies, mainly GBS variants acute inflammatory demyelinating polyneuropathy (AIDP)
and acute motor axonal neuropathy (AMAN), and chronic inflammatory demyelinating polyneu-
ropathy (CIDP). Then we characterized samples with anti-NF reactivity by isotyping, serial dilu-
tion, domain mapping, and for staining of nodal structures on tissue sections. Since we found
NF-reactivity in a small proportion of patients with AIDP and CIDP, we investigated possible in
vivo effects of anti-NF antibodies in a neuritis animal model, experimental autoimmune neuritis
(EAN), and report that anti-NF antibodies enhance and prolong disease in this model.
4.3.1 Serum screening for anti-NF antibodies
We have tested a total of 394 serum samples by both ELISA and cell-bound assay using flow
cytometry with human NF155 and NF186. Using ELISA, we found reactivity in 8/254 (3%)
patients with inflammatory neuropathies (5 CIDP, 3 AIDP, 0 AMAN), but in none of 140 con-
trols (Figure 4.17 A and B). Among these eight anti-NF positive patients, six (5 CIDP, 1 AIDP)
recognized only NF155, one (AIDP) recognized only NF186, and one (AIDP) recognized both
isoforms (Figure 4.17 A and B). In addition, six of the patients showed clear reactivity while two
were at the detection limit.
Using our cell-based assay, we found very strong reactivity to NF155 in two CIDP patients
(Figure 4.17 C). These two patients had also exhibited reactivity to NF155 by ELISA (Figure
4.17 A). In addition, four controls (1 other neurological disease (OND) with sensory symptoms,
3 healthy (HC)) exhibited reactivity to one NF isoform expressed on the cell surface, but did not
react by ELISA (Figure 4.17).
To further investigate the prevalence of human NF reactivity in CIDP patients, we tested an
additional cohort of 40 patient samples taken from plasma exchange material (Figure 4.17). We
found one donor with clear NF155 reactivity by ELISA, but not in the cell bound assay.
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Figure 4.17: Autoantibodies to NF155 and NF186 detected by ELISA and flow cytometry:
Serum samples from patients with CIDP (n = 118), AIDP (n = 65), AMAN (n = 50), ON (n = 20),
and controls OND (n = 61), HC (n = 77) were tested for autoantibodies to NF155 and NF186
by ELISA (A,B) and flow cytometry (C,D). Plasma exchange material from an additional cohort
of CIDP patients (CIDP*; n = 40) were tested. ELISA reactivities to NF155 (A) and NF186
(B) are shown as baseline-subtracted optical density reading at 450 nm (∆OD450; response
to NF minus BSA reactivity). Reactivity by flow cytometry is shown as mean fluorescence
intensity (MFI) ratio (reactivity to NF transfectants divided by reactivity to control cells). The
cutoff (dashed line) represents the mean of OND group plus four standard deviations. The
special symbols are each representative of one serum sample.
Since a previous report (Pruess et al., 2011) found a higher average reactivity to ratNF155-
NS0 by ELISA in GBS patients compared to healthy controls, we also used this antigen for
serum screening in parallel with the HEK293-derived protein. As in that report, we found broad
reactivity to ratNF155-NS0. However, we did not observe a significant difference between the
GBS group (AIDP and AMAN; n = 115) compared to the control group (OND and HC; n = 138).
The patients who showed reactivity to the NF155/NF186 by ELISA were not conspicuous with
ratNF155-NS0 (gray symbols; Figure 4.18). Nonetheless, as shown earlier in Section 4.2.2.1,
we believe that ratNF155-NS0 is not a specific antigen to identify antibodies against human
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NFs and would consider data obtained with this antigen with caution.
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Figure 4.18: ELISA screening with ratNF155-NS0: Serum screening by ELISA using
ratNF155-NS0 (A) included samples from patients with CIDP (n = 82), AIDP (n = 54), AMAN (n
= 50), and controls OND (n = 61), HC (n = 77). The delta OD (response to ratNF155-NS0 mi-
nus BSA reactivity) is shown. Most of the patients and control donors show a response against
this antigen. The mean of each group is shown. Filled circles represent positive samples from
ELISA or flow cytometry using NF155 and NF186.
4.3.2 Detailed analysis of NF-reactive serum samples
We further characterized the anti-NF reactivities detected in the two patient samples by both
assays and the four highest by only ELISA, as well as four control samples by flow cytometry
(Figure 4.17).
Two CIDP patients (43 yr old Japanese female and 76 yr old German female) showed high
IgG reactivities to NF155 by both ELISA and cell-based assay (Figure 4.17 A and C). In both
patients, the anti-NF155 reactivities were detected at serum dilutions of 1:1000 up to 1:10 000
in both assays (Figure 4.19 B and E, Figure 4.20 B and E). In one of the two patients, we
also tested cerebrospinal fluid and found NF155 reactivity (Figure 4.20 D). The dominant IgG
subclass was IgG4 in both cases, with minor contribution from IgG1, IgG2, IgG3, and IgM, IgA
(Figure 4.19 C and F, Figure 4.20 C and F). To identify the domains that were recognized by
these autoantibodies, we expressed truncated variants of NF155 and NF186 on the surface of
TE671 cells. Autoantibodies from both patients recognized only one fragment unique to NF155
spanning the Fn3-Fn4 domains (Figure 4.19 I, Figure 4.20 I). We further analyzed whether these
autoantibodies also recognized NF155 on tissue sections. NF155 is known to be localized in
the paranodes in both the CNS and PNS (Poliak and Peles, 2003). Serum from both patients
stained paranodes on rat tissue sections that are marked by anti-Caspr antibody staining as a
paranodal marker (Peles et al., 1997) (Figure 4.19 G, Figure 4.20 G).
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Figure 4.19: A Japanese CIDP patient with high NF155 reactivity: Reactivity to NF155 was
seen by flow cytometry (A,B,C) up to a dilution of 1:10 000 (B). (A) Reactivity to NF155 (blue
line) was compared with reactivity to NF186 (orange line) and to control cells (black, filled).
(C)The NF155 reactivity was mediated by IgG4 with minor contribution from IgG1. Reactivity
to NF155 was also seen by ELISA (D,E,F) up to a dilution of 1:10 000 (E) by IgG4 and weakly by
IgG1, IgG3, IgM, and IgA (F). Serum staining (G, left) colocalizes with Caspr staining (G, middle)
on longitudinally cut rat spinal cord sections. The scale bar represents 10µm. (H) NF186 differs
from NF155 by substitution of Fn3-Fn4 with Fn4-Mucin-Fn5. (Ig = immunoglobulin-like domain;
Fn = fibronectin type III domain) (I) A scheme of super green fluorescent protein (sGFP) fusion
truncated NF variants is shown beside the corresponding serum reactivity by flow cytometry.
Reactivities to truncated NF variants and to negative control cells are shown as sGFP intensity
versus serum reactivity. The fragment recognized by both NF155-reactive serum samples is
boxed.
CHAPTER 4. RESULTS 72
Figure 4.20: A German CIDP patient with high NF155 reactivity: Reactivity to NF155 was
seen by flow cytometry (A,B,C) up to a dilution of 1:10 000 (B). (A) Reactivity to NF155 (blue
line) was compared with reactivity to NF186 (orange line) and to control cells (black, filled).
(C)The NF155 reactivity was mediated by IgG4. Reactivity to human NF155 was also seen
by ELISA in serum and cerebrospinal fluid. Serum reactivity by ELISA (D,E,F) was seen up
to a dilution of 1:10 000 (E) by IgG4 and weakly by IgG3 and IgA (F). Serum staining (G, left)
colocalizes with Caspr staining (G, middle) on longitudinally cut rat spinal cord sections. The
scale bar represents 10 µm. (H) NF186 differs from NF155 by substitution of fibronectin (Fn)
domains Fn3-Fn4 with Fn4-Mucin-Fn5. (Ig = immunoglobulin-like domain; Fn = fibronectin type
III domain) A scheme of super green fluorescent protein (sGFP) fusion truncated NF variants is
shown beside the corresponding serum reactivity by flow cytometry (I). Reactivities to truncated
NF variants and to negative control cells are shown as sGFP intensity versus serum reactivity.
The fragment recognized by both NF155-reactive serum samples is boxed.
A patient fulfilling clinical and electrophysiological criteria of motor-dominated CIDP (44 yr old
German male) had antibodies to NF155 as detected by ELISA. Extensive antibody tests for
onconeuronal, rheumatologic, autoimmune, neuronal surface antigen and neuropathy-related
antibodies were negative in this patient. In detail, this patient tested negative for antibodies
against Hu, Yo, Ri, amphiphysin, GAD65, MOG, TPO, TG, aquaporin-4, gangliosides (GM1,
GM2, GM3, GD1a, GD1b, GT1b, GQ1b), AChR, ANA, ENA, cANCA, pANCA, VGKC, VGCC,
MuSK, Ma1, Ma2, CV2, NMDA, GABAb, AMPA, Lgi1, and Caspr2. He developed progres-
sive relapsing paralysis in his distal arm and hand. During the first 6 months, he completely
responded to treatment with high-dose steroids and intravenous immunoglobulin (ivIG). Sural
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nerve biopsy indicated demyelination. The paralysis progressively worsened to tetraparesis
including facial and respiratory muscles, and he became unresponsive to steroids and ivIG.
By electromyography (EMG) he showed multiple conduction blocks. Plasma exchange (PE)
was found to be very efficient to rapidly and completely relieved paralysis, but frequency of
PE increased from once a month to 3-4 times a week. Remarkably, with PE the patient re-
gained reflexes within a few days, suggesting a functional disturbance rather than structural
damage. Three years after initial presentation, he received an autologous stem cell transplant
in 2010. Several months afterwards, frequency of PE was reduced to once a week, and he was
finally weaned without reoccurrence of paralysis. We were able to monitor the anti-NF reactivity
throughout the disease course. The NF155 reactivity persisted throughout this observation pe-
riod while showing a progressive decline after the 2009 time point (Figure 4.21 A). The anti-NF
antibodies were predominantly IgG3 by ELISA (data not shown). We affinity purified anti-NF
antibodies against both NF155 and NF186 from plasma exchange material, and eluted IgG3,
as well as small amounts of IgG1, IgM, and IgA (data not shown). These antibodies were reac-
tive NF155 by ELISA and also by cell-based assay, and additionally a low reactivity to NF186
in both assays (Figure 4.21 B-D).
Another CIDP patient (64 yr old German male) who benefited from plasma exchange also
showed NF155-specific antibodies which were IgM, IgA, IgG3, IgG2, IgG1 (in the order of
contribution to the reactivity observed by ELISA). Three patients with AIDP (83, 59, 34 yr old
Japanese males) showed reactivities to NF at serum dilution of up to 1:1000 by ELISA. They
tested negative for anti-ganglioside antibodies. The first exhibited antibodies to only NF155
with IgG1, the second to only NF186 with IgG1, and the third to both NFs with IgG1 and IgG3
(data not shown).
Four control samples also showed NF reactivities at serum dilution 1:1000 by flow cytometry
and not by ELISA. These samples were from a patient (33 yr old Swedish female) with sensory
symptoms (classified OND), and three healthy controls (46, 47, 47 yr old Japanese females).
The OND control patient had anti-NF186 IgG3 antibodies, one healthy control had anti-NF155
IgG1, and the other two healthy controls had anti-NF186 IgG1 (data not shown). The NF155-
reactive samples showed reactivity only to the NF155-unique truncation mutant expressing
Fn3-Fn4 domains while NF186-reactive samples recognized NF186-unique fragments span-
ning Fn4-mucin-Fn5, and also mucin-Fn5 alone (data not shown). The other 62 OND control
donors and 74 healthy controls were tested negative for NF reactivity by both assays. All the
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Figure 4.21: NF155 reactivity in a CIDP patient benefiting from plasma exchange: Anti-
NF155 reactivity by ELISA persisted over years in one CIDP patient, and after affinity purifica-
tion, low level reactivity was seen by ELISA and flow cytometry to both NF155 and NF186. (A)
By ELISA, reactivity to NF155 (blue), but not NF186 (orange) was found in samples taken from
2008, 2009, 2010, and two time points (February (a) and October (b)) in 2011. Reactivities
were measured at the same Ig concentration for each time point. (B-D) Anti-NF antibodies
were purified from plasma exchange (PE) material from 2011a against NF155 and NF186. By
flow cytometry (B), original PE material was not reactive to either NF (NF155, blue line; NF186,
orange line), but NF155-purified antibodies showed binding to both isoforms. By ELISA (C,D),
serial dilution of PE material and purified antibodies was done (C) NF155 was recognized by
the original PE material and by antibodies from both NF columns. (D) NF186 was recognized
by only purified antibodies from both NF columns but not by the original PE material.
positive samples found by either assay were tested for nodal or paranodal binding on tissue
sections by immunohistochemistry, only the two highly reactive CIDP patients showed a clear
paranodal staining pattern (Figures 4.19 and 4.20).
4.3.3 Effects of anti-NF antibodies on experimental autoimmune neuritis
We investigated possible in vivo effects of NF targeting by antibodies in peripheral nerve by
utilizing an EAN rat model. EAN was induced by active immunization with P2-peptide and clin-
ical disease was observed 14 days later. We tested two different anti-pan-NF mAbs (A12/18.1
mouse IgG2a and A4/4.3 mouse IgM) separately. At disease onset 500 µg of mAb or the
respective isotype control was injected intravenously. Both anti-NF mAbs rapidly increased
disease severity and prolonged disease duration compared to isotype controls (Figure 4.22).
Rats treated with mouse IgG2a anti-NF mAb A12/18.1 showed a clinical score of 2.4 ± 0.4
(mean ± SEM; n = 6) at the peak of disease, compared to 1.1 ± 0.3 (mean ± SEM; n = 6) in rats
treated with isotype control. Disease duration in rats injected with anti-NF mIgG2a was 26 days
compared to only 11 days with isotype control treatment. Rats treated with mouse IgM anti-NF
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mAb A4/3.4 showed a clinical score of 2.4 ± 0.3 (mean ± SEM; n = 6) at the peak of disease,
compared to 1.3 ± 0.2 in rats treated with isotype control. Disease duration after anti-NF mIgM
injection was 24 days, compared to 17 days with the isotype control. Na’́ive rats injected with
either anti-NF mAb without prior P2-peptide immunization (n = 3 per antibody treatment) did
not show any signs of clinical disease during an observation period of 15 days, implying that
antibody treatment alone is not enough to cause disease. (Dr. Naoto Kawakami performed the
experiments and collected the data.)
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Figure 4.22: Two different mAbs to NF enhance experimental autoimmune neuritis: Lewis
rats immunized with P2-peptide were injected with either anti-pan-NF mAb A12/18.1 mouse
IgG2a (A) or A4/3.4 mouse IgM (B) (closed symbols) or their respective isotype controls (open
symbol) at disease onset (day 14 after EAN induction, indicated by arrowhead). They were
scored daily for EAN disease severity. Values (mean ± SEM) represent EAN clinical scores
from 6 rats per group, pooled from 2 independent experiments.
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4.4 Neurofascin-specific autoantibodies in multiple sclerosis
In this study, we asked if anti-NF antibodies are present in serum of patients with MS. We
included patients with relapsing-remitting MS as majority, and patients with primary and sec-
ondary progressive MS. In addition, we used serum from a few patients with clinically iso-
lated syndrome (CIS). For comparison we included as controls a cohort of patients with non-
demyelinating disease amyotrophic lateral sclerosis (ALS), patients with other neurological dis-
eases, and healthy controls. The serum samples were analyzed by flow cytometry, ELISA and,
to a limited extent, Western blot. Afterwards, the NF-reactivity of positive samples was further
characterized by isotyping, serial dilution, domain mapping, and for staining of nodal structures
on tissue sections. The control samples included in this study were from the same cohort that
was reported in the peripheral inflammatory neuropathy study. To increase the sensitivity of
anti-NF antibody detection, we performed affinity-purification using plasma exchange material
from 8 RR-MS patients and tested the eluted antibodies for NF reactivity in our assays.
4.4.1 Serum screening for anti-NF antibodies
We have tested a total of 429 serum samples by both ELISA and cell-bound assay using flow
cytometry with human NF155 and NF186. Using ELISA, we found 4/225 MS and 2/68 ALS
samples with low reactivity to NF155, but not to NF186, and no reactivity was observed in
5 CIS, 61 OND, and 77 HC donors (Figure 4.23 A and B). By flow cytometry, we found NF-
reactivity in 3/225 MS patients, 1/61 OND controls and 3/77 healthy controls (Figure 4.23 C
and D). In detail, 2 MS patients (one is at the detection limit) showed reactivity to NF155, and
the other to NF186; 1 healthy donor also showed NF155 reactivity while another 2 healthy
donors and 1 OND donor showed reactivity to NF186.
We also screened a random selection of 44 MS (43 RR-MS and 1 PP-MS), 36 OND samples
and 4 healthy controls by Western blot to the denatured human NF155 and NF186. We found
57% reactivity in the MS group and 53% reactivity in the OND group, indicating that by Western
blot screening there was no significant difference (Figure 4.24).
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Figure 4.23: Autoantibodies to NF155 and NF186 detected by ELISA and flow cytometry:
Serum samples from patients with MS (n=225), CIS (n=5), ALS (n=68), and controls OND
(n=61), HC (n=77) were tested for autoantibodies to NF155 and NF186 by ELISA (A,B) and
flow cytometry (C,D). ELISA reactivities to NF155 (A) and NF186 (B) are shown as baseline-
subtracted optical density reading at 450 nm (∆OD450; response to NF minus BSA reactivity).
Reactivity by flow cytometry is shown as mean fluorescence intensity (MFI) ratio (reactivity to
NF transfectants divided by reactivity to control cells). The cutoff (dashed line) represents the
mean of OND group plus four standard deviations.
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Figure 4.24: Autoantibodies to NF155 and NF186 detected by Western blot: (A) Example
blots containing NF155 (lane 1) and NF186 (lane 2) stained with anti-HIS mAb and serum that
were non-reactive, reactive to only NF155, NF186, or both isoforms are shown. Serum samples
were diluted 1:400. (B) Total number of serum samples from MS groups and control groups that
showed reactivity to either NF155 or NF186, or to both isoforms. The total number of samples
investigated is indicated next to the patient group.
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4.4.2 Characterization of serum samples showing anti-NF reactivity
We further characterized the anti-NF reactivities detected by ELISA and FACS in the MS and
ALS patient serum samples by performing serial dilutions, isotyping, epitope mapping by flow
cytometry, and immunohistochemistry on longitudinal spinal cord sections.
One sample (from 43 yr old Swedish female) showed NF155-reactivity up to 1:1000 dilution
using IgG, however the reactivity was not detected with IgG subclass specific antibodies (Figure
4.25 A and B). The observation indicated that the sensitivity for detecting human IgGs was
higher using polyclonal goat anti-human IgG secondary antibody that were specific for multiple
epitopes on the antibodies compared to mouse monoclonal antibodies against their specific
epitope on specific IgG subclasses. The other NF155-reactive sample (34 yr old Swedish
male) showed low reactivity to NF155 (barely detectable at 1:300 dilution) using IgG1. We
obtained follow-up serum taken from this patient 3 years afterwards, and found that the NF
reactivity had disappeared (Figure 4.25 C and D). We noted that this patient had received a
bone marrow transplant within this period and did not require MS treatment afterwards.
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Figure 4.25: Anti-NF155 reactivity in 2 RR-MS patients: (A, C) Serum reactivities to only
NF155 were seen by flow cytometry. (B, D) The reactivities, shown as mean fluorescence
intensity (MFI) ratio, were isotyped for specific IgG subclasses. In D, reactivities of the original
sample and a followup sample taken 3 yrs afterwards are shown.
A third RR-MS patient (33 yr old Iranian male) showed NF186-reactivity by IgG3 which could be
detected up to 1:3000 dilution (data not shown). This reactivity was directed against the Mucin-
Fn5 region of NF186 (Figure 4.26 C and D). From this patient we also found NF186 reactivity
in CSF at a comparable level as in serum (Figure 4.26 A). In addition, we obtained follow-
up serum, confirmed the persistence of anti-NF186 reactivity, and were able to affinity purify
approximately 25 µg of antibodies from 12 mL of serum using a NF186-conjugated sepharose
column. Despite the presence of IgM and IgA in addition to IgG, reactivity to NF was mediated
only by IgG and was detected only by flow cytometry directed only against NF186. These
reactive antibodies were IgG3, and we confirmed that they weakly recognize the Mucin-Fn5
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region of NF186 (Figure 4.26 B). We had also tested these antibodies for nodal binding on rat
spinal cord sections, but we did not find a clear nodal staining pattern.
Figure 4.26: Anti-NF186 reactivity in an RR-MS patient: (A) In both serum and CSF, reactiv-
ity to NF186 (orange line) but not to NF155 (blue line) was shown by flow cytometry when com-
pared to mock transfectants (black, filled). (B) IgG3 reactivity was found by flow cytometry in
serum taken in 2007 and in 2010. (C,D) Staining of truncated NF variants for epitope mapping.
(C) Scheme of the extracellular domains of NF155 and NF186. NF186 differs from NF155 by
substitution of Fn3-Fn4 with Fn4-Mucin-Fn5. (Ig = immunoglobulin-like domain; Fn = fibronectin
type III domain) (D) A scheme of super green fluorescent protein (sGFP) fusion truncated NF
variants is shown beside the corresponding serum reactivity by flow cytometry. Reactivities are
shown as sGFP intensity versus serum reactivity. Weak reactivity to (Fn4-)Mucin-Fn5 region
was observed (boxed), and no reactivity was seen against the other fragments of NF.
By ELISA, 4 RR-MS patient samples (46, 52, 55 yr old female, 47 yr old male) showed low
reactivity to NF155. Two of these samples show anti-NF IgM and IgA. Another showed low IgA
reactivity only and the last exhibited reactive IgG3 in addition to IgM and IgA (data not shown).
Two ALS patient samples (58, 75 yr old German females) showed low reactivity to NF155. They
both had IgM and IgA antibodies, and in addition IgG3 in one sample (data not shown). Reactiv-
ity to NF found in the control groups were previously discussed in section 4.3.2. All the positive
samples were additionally tested for nodal or paranodal staining by immunohistochemistry on
tissue sections and we did not observe such staining patterns in these samples.
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4.4.3 Affinity purification of anti-NF antibodies from RR-MS plasma exchange
material
We asked if anti-NF antibodies are perhaps present in the serum of MS patients at a level
that is beyond the lower detection limit of our screening assays. We purified antibodies by
affinity chromatography using sepharose columns conjugated with either NF155 or NF186.
The purified antibody preparations were then tested for binding to NF155 and NF186 by ELISA
and flow cytometry, and the isotype of NF-reactive Igs were determined.
4.4.3.1 Purification of anti-NF antibodies from plasma exchange material
Antibodies to NF155 and NF186 were purified in parallel from plasma exchange material col-
lected from 8 RR-MS patients by affinity chromatography (described in Section 3.5.8). From
200 mL of plasma exchange, between 30 - 275 µg of antibodies (pooled from different pH elu-
tion fractions) were eluted against each isoform of NF. Details are found in Table 4.2. ivIG was
used as to control for the antibody purification experiments.
Table 4.2: Plasma exchange material from RR-MS patients: unpurified original material, puri-
fied anti-NF155 and anti-NF186 antibodies
Antibody amount
Sample
ID
Gender Age Response to PE Unpurified total
(mg)
NF155-purified
(µg)
NF186-purified
(µg)
MS-010 F 39 n.a. 1680 276 30
MS-011 M 32 Yes 1000 120 120
MS-012 M 52 Yes 1520 75 82
MS-028 F 50 Yes 1200 120 93
MS-029 M 22 No 1480 132 175
MS-030 F 42 Yes 900 143 41
MS-031 F 48 Yes 1390 150 100
MS-032 F 30 Yes 1700 250 200
ivIG - - - 500 40 77
Each purified antibody preparation was visualized by gel electrophoresis and bands of inter-
ested were identified by mass spectrometry. By SDS-PAGE, IgM was the most abundant,
followed by IgG and IgA for all preparations made. In addition, a low amount of albumin was
also found. An example gel is shown in Figure 4.27.
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Figure 4.27: Purified antibodies visualized by silver-stained SDS-PAGE: Antibodies puri-
fied from one RR-MS patient plasma exchange material (MS-030) against NF155 and NF186.
Antibodies were eluted at pH 5, pH 4, and pH 3, and separated using SDS-PAGE in reducing
and non-reducing conditions. Red boxes indicate bands (1-6) that were cut out for identification
by mass spectrometry. The identity of each numbered band is listed on the right of the gel.
4.4.3.2 Reactivity of purified antibodies by ELISA and flow cytometry
The antibodies eluted from the NF155 and NF186 columns were tested for reactivity by ELISA
and by flow cytometry (Figure 4.28). At 5 µg/mL, all 8 antibody preparations from patient PE
material and antibodies isolated from ivIG using the NF155 column showed clear reactivity to
NF155 (∆OD450 > 0.1), and only one patient preparation (MS-030) additionally showed clear
reactivity to NF186. With antibodies purified from the NF186 column, we observed clear NF186
reactivity in only 2 of the 8 patients (MS-010, MS-030), weak reactivity in another (MS-010),
and not in ivIG; in 4 of the 8 patients (MS-010, MS-011, MS-029, MS-030) we found reactivity to
NF155 (Figure 4.28 A). The reactivities seen with antibody preparations from RR-MS patients
were mediated predominantly by IgM and to a lower extent IgA, IgG3 antibodies were further
detected in two of these patients and IgG1 antibodies in another one (Figure 4.28 C). A strong
reactivity (∆OD450 > 0.5) mediated by IgG was seen in 1 of 8 patient samples, by IgM in 5 of
8, and by IgA in 3 of 8 (Figure 4.28 C).
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Figure 4.28: NF-reactivity of purified antibodies: Unpurified PE material and antibodies pu-
rified against NF155 and NF186 from 8 RR-MS PE material were tested for reactivity to NF155
(blue) and NF186 (orange) at 5 µg/mL by ELISA (A) and flow cytometry (B). Antibodies puri-
fied from ivIG were additionally tested as a control. (A) ELISA reactivities of the unpurified PE
and purified antibodies from both the NF155-column and NF186-column are shown as ∆OD450
(reactivity to NF minus reactivity to BSA). Our cutoff criteria is ∆OD450 = 0.1. (B) We show the
reactivities observed by flow cytometry of the original PE material and antibodies purified from
NF155 column. The fluorescence intensities measured on NF55- and NF186-expressing cell
lines are compared to mock transfectants (black; filled). In (A) and (B), reactivities of total Ig
are shown. (C) The isotype of antibodies responsible for the NF reactivity was analyzed by
ELISA.
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By flow cytometry, 3 of the 8 RR-MS patient antibody preparations (MS-010, MS-012, MS-031)
from the NF155 column showed reactivity to NF155, another one (MS-032) showed weak anti-
NF155 reactivity (Figure 4.28 B), and none showed reactivity to NF186 (data not shown). The
anti-NF155 reactivities observed were directed against an epitope on the Fn3Fn4 fragment (Fig-
ure 4.29 B and C). Interestingly, the dominant Ig-isotype conveying this reactivity was different
between these four preparations, one used IgG1, two others used IgM, and the last IgA (Figure
4.29 A). Antibodies purified from ivIG also showed very faint signal on NF155 cells (Figure 4.28
B). Antibodies purified over the NF186 column did not show reactivity by flow cytometry.
Figure 4.29: Characterization of NF155-specific antibodies reactive by flow cytometry:
(A) NF155-column purified antibody preparations that showed NF155-reactivity were isotyped.
(B) A scheme of the extracellular domains of the complete NF155 and NF186 is shown. NF186
differs from NF155 by substitution of Fn3-Fn4 with Fn4-Mucin-Fn5. (Ig = immunoglobulin-like
domain; Fn = fibronectin type III domain) (C) The specific domain reactivity of MS-012 is shown.
A scheme of super green fluorescent protein (sGFP) fusion truncated NF variants is shown
beside the corresponding reactivity by flow cytometry. Reactivities are shown as sGFP intensity
versus serum reactivity. The specific domain recognition of the NF155 reactivity was mapped
to the Fn3Fn4 fragment (boxed).
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5.1 Summary of findings
We cloned and recombinantly expressed human neurofascin 155 and 186 in human cell lines.
Using the recombinant NFs, we developed assays to detect antibodies against human NF: cell-
based assay by flow cytometry, ELISA and Western blot. We also demonstrated that ratNF155-
NS0, an antigen used in previous studies for detection of NF-autoantibodies, is not a suitable
antigen due to immunogenic post-translational modifications from the host cell line NS0. An-
tibodies against NF were found by ELISA in a small proportion (3%; 8/254) of patients with
inflammatory neuropathies and none of the controls. Two strongly ELISA-reactive CIDP sam-
ples were also reactive by flow cytometry to NF155. Another CIDP patient who benefited from
plasma exchange showed anti-NF155 reactivity by ELISA, and after affinity purification addi-
tional reactivity to NF186 and also by flow cytometry. We tested the pathogenic potential of
antibody targeting of NF in a peripheral inflammatory nerve disease setting using mAbs, and
found that the mAbs could exacerbate disease although they could not induce disease on their
own. Anti-NF reactivity was detected in a small proportion of MS patients (3%; 7/225) by flow
cytometry and ELISA. To increase detection sensitivity of NF antibodies in RR-MS patients, we
affinity-purified NF-reactive antibodies from plasma exchange material, and found antibodies
reactive to NF155, and to a lesser extent to NF186. Serum reactivities observed against NF by
flow cytometry and ELISA were isoform-specific and assay-specific in most cases, and using
mainly IgG subclasses. Using truncated variants of NF, we mapped the antibody specificity of
NF155-reactive antibodies to the Fn3-Fn4 region and the Muc-Fn5 region for NF186-reactive
antibodies.
5.2 Assay comparison and evaluation
Human cell lines were employed to recombinantly express human isoforms of NF155 and
NF186 to detect anti-NF antibodies in patients with autoimmune diseases of the nervous sys-
tem. That the antigens were as similar as possible to what are physiologically seen by anti-
bodies was crucial for our approach. By using our human protein antigens, we avoided detect-
ing antibodies against non-human amino acid sequences and non-human cell-specific post-
translational modifications. To illustrate the importance of this aspect, we compared the utility
of our human NFs to a commercially available rat isoform of NF155 that was produced in NS0
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mouse myeloma cells in an ELISA format. While about 3% of all patients showed reactivity
by ELISA to the human NFs, virtually every sample showed clear reactivity (at various lev-
els) to the rat NF155. Upon further examination using antibodies purified against rat NF155,
we discovered that the post-translational modifications imposed onto the protein antigen by
the murine host cells is likely a major contributing factor to the reactivites detected in patient
sera. It is known that the murine NS0 cells produce abnormally glycosylated proteins that are
potentially immunogenic depending on culture conditions (Walsh and Jefferis, 2006). Further-
more, potentially relevant human NF epitopes may be absent or masked by such modifications.
Together, it is evident that the ratNF155-NS0 is not a suitable antigen for anti-NF antibody de-
tection studies, and this highlights the importance of using human antigens that are expressed
in appropriate cell lines, as requested by Willison (2011) in a reply to the NF-antibody study
published by Pruess et al. (2011).
For this project, we developed antibody detection assays: ELISA, cell-based assay by flow
cytometry, and Western blot. Each assay has inherently unique properties that determine how
the antigen is displayed. The properties that directly influence antibody binding include the
conformation of the protein antigen, the orientation, and the density.
For flow cytometry, NFs were expressed on the surface of human cell lines in presumably its
native conformation and correct orientation at a density determined by transfection efficiency.
The advantage of this method is that the antigen was unlikely to be unfolded and is properly
oriented and could be used to detect physiologically relevant antibodies, although its physio-
logically relevant binding partners necessary for complex formation were absent.
The antigen was theoretically denatured (and, in some experiments, reduced) for the Western
blot assay. This implies that only linear epitopes were presented to antibodies. Such linear
epitopes were in a conformation that was likely different from that of the corresponding region
in the intact protein (van Regenmortel, 2000). The density of the antigen depended on the
amount of protein used for blotting and also blotting conditions.
In the ELISA, the protein antigen was immobilized according to the surface chemistry of the solid
support at a density defined by the user. We chose a matrix that preferentially binds hydrophilic
molecules (ex. protein surface carbohydrate moieties) instead of hydrophobic surfaces (ex.
inner core of a folded protein) to avoid completely denaturing the protein antigen. However,
we could not exclude that the NFs were manipulated in a way that their native conformation
was altered to expose hidden epitopes or to mask antigenic epitopes rendering false-positive
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or -negative result. In addition, the antigen density in an ELISA assay was dependent on the
concentration of coating solution and efficiency of the coating process.
Each method has advantages and disadvantages. They reflect our current understanding of im-
munoassays and illustrate the utility of the current available methods of detection. We screened
a collection of patient serum from patients with GBS, CIDP, and MS along with other controls
with our ELISA and flow cytometry assay. For a small subset, we also performed Western blot
analysis. Interestingly, the majority of NF-reactive samples were positive only by ELISA but not
flow cytometry, or vice versa. This was true in both the patient group and the control group.
Only in 2 samples did we find (strong) reactivity in both assays. It is difficult to elucidate the
reason for this disparity because we do not know the exact epitope(s) on the antigen responsi-
ble for the reactivities observed. Evidence suggesting the potential pathogenicity of antibodies
that were identified by ELISA but not by flow cytometry came from work using rabbit antibodies
generated against a peptide of NF155. These rabbit antibodies were reactive by ELISA but
not flow cytometry, stained paranodes on tissue sections, and caused complement-dependent
demyelination in an in vitro myelination culture model (unpublished data from Dr. Chris Lining-
ton). Our initial Western blot analysis revealed broad reactivity in both MS patient group and
controls; in only one patient sample showing reactivity against NF186 did we also find reactivity
by flow cytometry. Endogenous antibodies against denatured proteins, which may be found in
necrotic cellular debris such as degenerating myelin, have been shown to accumulate at sites
of nerve injury and has a role in promoting repair by clearance of cell debris; these antibodies
were thought to recognize degenerate tissue as non-self (Vargas et al., 2010). Considering
this point, antibodies reactive only towards denatured nerve antigens may not have a direct
role in disease pathogenesis. However, as seen with pathogenic mAbs (ex. A12/18.1 and
A4/3.4) that recognize NF by Western, flow cytometry, ELISA and also in vivo, antibodies that
are not exclusively detected by Western blot may have a pathogenic role (Mayer and Meinl,
2012).
We performed immunohistochemistry with the NF-reactive serum samples and some negative
samples chosen at random using longitudinally-cut frozen rat tissue sections. On the sections,
NF155 and NF186 were in complex with their binding partners and presented at natural den-
sities. We found clear paranodal staining for NF155 in only CIDP patient samples that also
showed reactivity by ELISA and flow cytometry. With the other samples identified by either
ELISA or flow cytometry, however, no nodal staining pattern was observed. This may be due to
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alteration of NFs by the fixation procedure, the lower density of NFs presented compared to the
other assays, or lack of crossreactivity directed to rodent NFs. Furthermore, the signal-to-noise
ratio was evidently worse compared to the assays using recombinant NF. For these reasons,
we also did not employ immunohistochemistry as a method for serum screening.
In addition, we isolated anti-NF antibodies by affinity chromatography from patient material
where we suspected antibody presence that exceeds the lower detection limit of our assays.
The isolation procedure and subsequent storage conditions can affect antibody structure, ergo
its function and specificity (Omersel et al., 2010). The elution procedure was determined by
optimizing a balance between purity, yield, and preservation of the natural immunoreactivity of
the antibodies. Antibody-antigen binding is a combination of ionic and hydrophobic interactions,
hydrogen bonds, and van der Waal forces. Elution of bound antibodies involves breaking such
interactions through altering the ionic strength, pH, temperature, and by using organic solvents
(Howard, 1981). We performed successive elutions with buffers at pH 5, pH 4, pH 3, and pH 11,
while neutralizing the column between each step. We found higher reactivity in fractions eluted
at pH 5 and pH 4 compared to pH 3, and still lower reactivity at pH 11. The small amounts
of eluted antibodies were concentrated and Ig-free BSA was added as a stabilizer to prevent
loss through surface adsorption. When we tested these isolated antibodies that come from
unreactive original plasma exchange samples, we found NF-reactivity by ELISA (higher than
∆OD450 = 0.2) in all of the preparations and reactive by flow cytometry in a few. The reactivity
observed was likely due to the much higher concentration of NF-reactive antibodies, however,
we cannot exclude that some of these antibodies may harbour subtle structural alterations
which make them additionally more reactive in our assays.
5.3 Anti-NF antibodies in peripheral inflammatory neuropathies
Autoantibodies were implicated in disease pathogenesis in patients with GBS and CIDP, but the
antigenic target is unknown. We propose that in a small proportion of patients NF155 and/or
NF186 may be a target. Our anti-NF ELISA is evidently suitable for identifying subjects with
anti-NF antibodies among patients with inflammatory neuropathy and for distinguishing them
from controls.
We made the unexpected observation that in two CIDP patients the anti-NF155 autoantibodies
were largely IgG4 with an additional contribution of IgG1, IgG2, IgG3, and IgA. Anti-NF155
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IgG4 in these CIDP patients may have an antigen blocking function to impair myelination and
thereby nerve conduction, as IgG4 is generally known not to be complement-activating and it
does not bind Fc receptors on effector cells (Nirula et al., 2011). This blocking effect of IgG4
antibodies may be pathogenic. For example, in endemic pemphigus foliaceus, a blistering skin
disease, IgG4 antibodies against desmoglein 1 cause a direct disruption of the epithelial layer
leading to blister formation (Rock et al., 1989). In this case, the pathogenic role of IgG4 is
through antigen blocking, disrupting the normal function of the target protein, and not through
antibody-mediated effector functions or complement activation (Rock et al., 1989; Nirula et al.,
2011). Apart from IgG4, low level reactivity was found from IgG1, IgG2, IgG3, IgM, and IgA in
the two CIDP patients with the remarkably high anti-NF reactivity. These isotypes can activate
the complement cascade, and can recruit and amplify immune effector cell function.
One CIDP patient who benefited remarkably from plasma exchange had antibodies to NF, but
no reactivity to a broad range of onconeuronal, autoimmune and neuropathy-related antibodies.
This patient had largely anti-NF155 antibodies, and in addition, anti-NF186 antibodies which
were detectable after affinity purification. With escalation of immunotherapy, which involved
frequent plasma exchange therapy and an autologous bone marrow transplant in 2010, the
patient eventually remitted completely over the course of four years. Initially we saw an increase
of NF155 reactivity in this patient’s serum between 2008 and 2009, and it was followed by
a progressive decline of titers. It is tempting to speculate that the reduced anti-NF antibody
levels may be linked to the reduced dependence on PE, but we must consider that our EAN
animal studies showed that the antibodies alone are not pathogenic; rather they are one of
several distinct pathogenic components. Another CIDP patient that benefited from plasma
exchange also showed anti-NF155 antibodies and we may speculate a role of these antibodies
in pathogenesis. However, due to the insufficient amount of purified patient antibodies against
NF, we were not able to perform passive transfer experiments into our EAN model to test for
the functional significance of such antibodies.
5.4 Anti-NF antibodies in multiple sclerosis
Serum reactivity to NF was seen in only a few MS patients (3%) by flow cytometry and ELISA,
while a higher frequency (8/8) showed antibodies to NF after affinity purification, with the ma-
jority (5/8) showing strong reactivity. In the serum of one MS patient, we found persisting IgG3
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against NF186 by flow cytometry. These antibodies were additionally found in the paired CSF
sample at a comparable level as in the serum, showing no evidence for an intrathecal synthe-
sis.
As MS is a long-term smoldering disease, some patients may harbour low levels of pathogenic
antibodies that contribute to the myelin disruption observed. We suspected that anti-NF anti-
bodies may exist at low levels (undetected by our assays) in some patients, and substantiated
this suspicion by affinity-purifying these antibodies over NF-conjugated columns from plasma
exchange material. We found the majority of functional antibodies to be against NF155 rather
than NF186. The purified antibodies to NF were predominantly IgM, and in addition a high IgG
reactivity was seen in one sample and high IgA response was seen in three.
Some IgM are natural antibodies, antibodies produced without antigenic stimulation by B1 cells
without any somatic mutation; they typically exhibit low affinity reactivity with polyspecificity
(Groenwall et al., 2012) and can activate the complement system (Janeway et al., 2007). There
are also IgM that are produced after an immune response after somatic hypermutation in IgM
memory cells (Janeway et al., 2007; Seifert and Kppers, 2009). Some IgM have been shown to
promote remyelination by possibly cross-linking antigens on the oligodendrocyte surface due to
its pentameric structure to bring together molecules (Warrington and Rodriguez, 2010). Also,
they can prevent the stimulation of autoreactive B2 cells to regulate the production of IgG by,
for example, masking antigenic epitopes (Gupta, 2010). However, IgM may have a pathogenic
role, as in IgM monoclonal gammopathy-associated neuropathies (Mata et al., 2011). Serum
IgA (IgA1) exist as predominantly monomers, and has been shown to regulate autoimmunity
and inflammation through its Fc receptor (Jacob et al., 2008). However, in an aggregated form,
as immune complexes or macromolecular form, IgA can promote an active immune response
through activation of IgA receptors (Monteiro, 2010). Class-switched IgG antibodies are pro-
duced by activated B2 cells upon antigen stimulation and have undergone affinity maturation;
they can promote complement activation, activate immune cells, or have blocking functions
(Janeway et al., 2007). Besides IgM, there are also IgG and IgA natural antibodies, and they
can react to a wide range of self-antigens in a polyreactive manner (Spalter et al., 1999). It
would be interesting to perform sequence analysis of purified anti-NF antibodies to look for
evidence of somatic hypermutation in future experiments to elucidate the origins of these anti-
bodies. At present the collective function of the low levels of anti-NF IgM, IgA, and IgG has yet
to be clearly determined. The demonstration of a low concentration of autoantibodies in MS
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patients raises the possibility that these antibodies may contribute to the pathogenesis of this
chronic smoldering disease.
5.5 Potential pathogenic relevance of anti-NF autoantibodies
The pathogenicity of NF-antibody targeting in CNS demyelinating disease was previously shown
in an EAE model by Mathey et al. (2007). We investigated the pathogenic potential of NF-
reactive antibodies in peripheral inflammatory neuropathies using an EAN model, yielding two
main findings. First, antibodies to NF can enhance and prolong an ongoing neuritis. Sec-
ond, antibodies to NF alone are not pathogenic. Previous studies of this P2-EAN model have
demonstrated nerve infiltration by autoreactive T cells and macrophages, yet autoantibodies
were not implicated (Lonigro and Devaux, 2009). We added anti-pan-NF mAbs into this dis-
ease setting and found that NF targeting exacerbated disease. A similar observation was made
in studies using a T cell transfer EAN model in which addition of anti-myelin antibodies greatly
exacerbated disease (Spies et al., 1995). These observations support the ’two-hit’ model pro-
posed from EAE studies: it postulates that immune-mediated inflammation can open up the
blood-brain barrier or somehow alter endothelial cells so that antibodies can gain access into
the CNS tissue (Derfuss et al., 2009; Rudick and Trapp, 2009). In our animal studies, it may
be that P2-immunization-induced inflammatory mediators made the blood-nerve barrier leaky
so that anti-NF antibodies can access the peripheral nerve to mediate nodal disruption. In-
flammatory neuropathies are characterized by pronounced immune cell infiltration (Schneider-
Hohendorf et al., 2012; Prineas, 1981) that will open blood-nerve barrier and provide access to
autoantibodies.
Unexpectedly, almost all the serum reactivities observed were directed against only one isoform
of NF. This is surprising because NF155 and NF186 are splice variants such that the 8 extra-
cellular domains from the N-terminus are virtually identical, differing only in the two domains
closest to the transmembrane region (Basak et al., 2007). We expressed truncated variants of
NF155 and NF186, and identified the Fn3-Fn4 domains as the target for NF155-specific reactiv-
ity and Mucin-Fn5 domains for NF186-specificity. Previous studies of NF-autoantibodies in MS
patients using rodent isoforms of NF (Mathey et al., 2007) and in myelin-homogenate-induced
EAN rat models (Lonigro and Devaux, 2009) have suggested the involvement of antibodies
that bound both isoforms of NF. This observation of isoform specificity is unrefutable from our
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experiments, and this point is shown for the first time since NF-reactive autoantibodies have
been under investigation.
Would the isoform-specific recognition of NF by human autoantibodies be compatible with
pathogenicity? NF186 is displayed on the nodes of Ranvier and is directly accessible to an-
tibodies. It has been shown that antibody targeting of NF186 in the presence of complement
disrupts nerve conduction (Mathey et al., 2007). The anti-NF186 antibodies that we found in
two patients with AIDP and one with MS were of the complement activating isotypes IgG1 and
IgG3. In addition, antibodies to NF186 might hinder its binding to gliomedin (the ligand for
NF186) in the PNS and the interaction with astrocytic processes in the CNS, thereby resulting
in loss of axonal clustering of voltage-gated sodium channels that are needed for saltatory con-
duction (Eshed et al., 2005). Antibodies to NF155 found in some AIDP, CIDP, and MS patients
would be expected to be pathogenic only if their target at the paranodes becomes accessible.
Since a disruption of paranodal architecture is a feature of different nerve pathologies such as
ischemia and inflammation (Reimer et al., 2011; Maier et al., 2007), these antibodies could con-
tribute to the pathology. It has been reported that anti-NF155 antibodies can inhibit myelination
by blocking the formation of the Caspr/contactin - NF155 complex, which is a core structure at
paranodal loops for adhesion between axon and glial cell (Charles et al., 2002). Such a disrup-
tion of the paranodal junctions can result in severe reduction of conduction velocity even in the
absence of obvious demyelination (Sherman et al., 2005). In addition, NF155 antibodies may
also interfere with early events of remyelination; it has been shown that during early myelina-
tion NF155 localize mainly in oligodendrocyte cell bodies and major branches, and migrate to
the distal end of the processes with Caspr (Schafer et al., 2004), antibody binding may disrupt
NF155 localization for proper node of Ranvier formation. Since the majority of NF-reactive pa-
tients have antibodies directed against NF155, it is tempting to speculate that such antibodies
interfere with remyelinaton in patients.
5.6 Outlook
Autoantibodies to neurofascins may have a role in inflammatory diseases in both the CNS
and PNS. With the assays developed in this thesis, anti-NF antibodies were found in 4% of
patients with AIDP or CIDP, some of which showed high titres. The prognostic value of the
presence of anti-NF antibodies for response to plasma exchange remains to be clarified. In
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MS patients, anti-NF antibodies are typically detected only with very sensitive assay systems
involving prior antibody isolation. These antibodies may have a pathogenic role in this chronic
disease in axonal injury or remyelination failure. Interestingly, a recent proteomic study demon-
strated perturbed axoglial physiology to be a hallmark of the early events of MS pathogenesis
(Dhaunchak et al., 2012). Kamm and Zettl (2012) had hypothesized the existence of a common
autoimmune reactivity against myelin antigens that are present in both systems. It would be
reasonable to test patients with disorders that affect both the central and peripheral nerve for
antibodies against NF.
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